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Personalized medicine can be defined as the use of the combined knowledge (molecular analysis 
and symptoms) about an individual to predict disease susceptibility, disease prognosis, or 
treatment response and thereby improve that person's health. The goal is to perform specific 
analyses of the patient’s sample and other conventionally used indicators for creating an 
individualized treatment response for the patient that would yield better outcomes.  
In cancer, the approach of personalized medicine is to analyze the patient’s tumor biopsy for 
genetic mutations and gene expression alterations and use this data to provide targeted drugs 
specifically for that patient’s alterations. However, there are a significant number of cases where 
genomic analysis currently fails to identify effective drugs or applicable clinical trials. Towards 
this, intratumor heterogeneity represents a major obstacle to effective cancer treatment and 
personalized medicine as currently, cancer diagnosis is performed on biopsies of a small region of 
a tumor, which may not necessarily provide representative biological information for the tumor as 
a whole. Therefore, there is a need for platforms that can provide insights into this intratumor 
heterogeneity in a clinical setting and elucidate the spatial sub-clonal architecture within a tumor 
at a molecular level. In this thesis, we present a platform that performs spatial gene expression 
analysis on a tumor tissue section using a microchip and provides the spatial map of target mRNA 
biomarker in less than 2 hours. The microchip allows for on-chip picoliter real-time reverse 
transcriptase loop mediated isothermal amplification (RT-LAMP) reactions on a histological tissue 
section without any analyte purification while preserving the native spatial location of the nucleic 
acid molecules. A major challenge towards this goal was to perform automated microdissection of 
the tissue on the microchip while preserving the spatial orientation. This was solved by engineering 
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the chip design to have knife-like individual well edges and developing a novel tissue pixelation 
protocol. 
In the other subset of cases, where the molecular analysis of tumor biopsy does identify targetable 
genomic alterations, patients do not always respond to therapy. For such cases, strategies to 
confirm therapeutic efficacy of drug candidates or identify additional drug options would be 
beneficial to both clinicians and patients. In these cases, the approach of personalized medicine is 
to use the patient’s tumor biopsy sample to form and culture tumor organoids using a compatible 
three-dimensional culture platform and downstream perform empirical drug testing on these 
organoids to yield the best possible drug candidate for the patient. In this thesis, we also present a 
high throughput hanging drop 3D culture platform, performed on a microchip, with potential 
applications in cancer drug screening.  
We also explore the utility of other micro-nano scale biosensing and diagnostic platforms in 
enabling personalized medicine. Towards this, we demonstrate a label free ion-sensitive field 
effect transistor (ISFET) based microRNA sensing platform where we show robust detection of 
Let 7b microRNA, which is a biomarker for human lung, breast and prostate cancer, using a million 
transistors on a single chip. We have also explored the application of biosensing platforms for 
personalized medicine in infectious diseases. In this thesis, we demonstrate a point-of-care 
biosensing platform that can detect zika virus directly from a whole blood sample using real-time 
reverse-transcription loop-mediated isothermal amplification (RT-LAMP) and a smartphone-
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Chapter 1: Introduction 
 
In this thesis we show the development and application of novel micro-nano scale platforms for 
personalized medicine. The goal in personalized medicine is to perform specific analyses of the 
patient’s sample (saliva, urine, blood, tissue, etc.) and combine them with the patient’s symptoms 
and other conventionally used indicators for creating an individualized treatment response for the 
patient that would yield better outcomes. The platforms developed can be segregated into two 




1.1 Micro-nano scale platforms for personalized medicine in cancer 
 
Chapter 2 - In cancer, the intratumor heterogeneity poses a significant challenge for personalized 
cancer diagnosis and treatment selection. Existing therapies of cancers such as prostate cancer, 
target and eradicate the bulk of cells within a tumor but most patients go on to develop androgen-
independent disease that remains incurable by current treatment strategies1. This can be explained 
by the presence of cellular differences within a single tumor usually referred to as Tumor 
heterogeneity. More specifically, tumor heterogeneity refers to the presence of distinctly different 
subpopulations within a tumor capable of breeding true2. These subpopulations differ in 
characteristics such as cellular morphology, tumor histology, receptors, enzymes, tumorigenicity, 
resistance to treatment, metastatic ability and cytogenetic markers, among others3–7. In the current 
clinical setting, cancer diagnosis is usually done on biopsies of a small region of a tumor and due 
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to intra-tumor heterogeneity, this may not provide representative biological information for the 
tumor as a whole. This is shown in the Figure 1.1. The failure of the current cancer treatment 
strategies can be attributed to the fact that the cancer treatment drugs usually target only a 
subpopulation of tumor cells which are sensitive to it while the remainder of the cancer remains 
unaffected2.  To characterize and analyze this tumor heterogeneity, a spatially mapped gene 
expression analysis is required as the bulk analysis techniques would average out these intra-tumor 
cellular differences. In this chapter, we present a technique that performs on-chip picoliter real-
time reverse transcriptase loop mediated isothermal amplification (RT-LAMP) reactions on a 
histological tissue section without any analyte purification while preserving the native spatial 
location of the nucleic acid molecules. We demonstrate this method by amplifying TOP2A 
messenger RNA (mRNA) in a prostate cancer xenograft with 100µm spatial resolution and by 
visualizing the variation in threshold time of amplification across the tissue.   
 
Chapter 3 – In majority of cases of cancer patients, the genomic alterations that are identified in 
the molecular analysis don’t have any known targeted drugs. For instance, in a recent clinical trial 
(EXaCT-1) published in the journal Cancer Discovery, out of the 769 patient samples they 
sequenced for alterations using exome sequencing, only 3 patients had FDA approved targeted 
drugs8. Moreover, even for patients that have known targetable alterations, the patients don’t 
always respond to the targeted drugs. Figure 1.2 shows the overall approach for personalized 
medicine in cancer.  This highlights the need for three important issues: 
1. Building a database of mapped genomic profiles to data on drug sensitivity. This will help 
classify future patients to their most effective drug candidates. 
2. Performing empirical drug testing directly on organoids from patient sample in order to 
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recommend the best individualized drug combination for the said patient. 
3. Understanding how the individual tumors adapt in response to therapies to understand the 
context in which these agents are efficacious. This will help guide the future drug development. 
For all of the above, we need a high throughput three-dimensional culture platform that does not 
put any selective pressure on tumor evolution during culture, is compatible with drug testing and 
allows for study of individual tumor organoids using microscopy-based techniques. In this chapter, 
we demonstrate such a platform called “Nano hanging drop culture” where individual nano-litre 
sized (10.8nL) hanging droplets are held by capillary forces inside inverted silicon oxide-on-
silicon micro-wells in oil. Organoid formation happens in less than 1 day due to increased cell-cell 
interactions within the nano-droplet and without the need for any specific medium or matrices that 
can put selective pressure and bias tumor evolution during culture. Nano hanging drop organoids 
grown from human glioblastoma cell line and patient derived xenograft cells showed similar 
protein expression profiles to those observed in vivo in human tumor xenografts. Using both 
glioblastoma organoids and patient derived cell organoids, we also demonstrate the feasibility of 
drug testing directly on chip with real time microscopy-based monitoring of organoids for response 
to drug with days. Taken together, these results indicate the broad applications of our nano hanging 
drop in various biomedical applications such as drug discovery, tissue engineering, and stem cell 
research. Although several three-dimensional culture techniques currently exist to produce 
organoids, they do not allow real time microscopy-based characterizations and individual organoid 
tracking, or high-resolution confocal analysis directly on the platform while avoiding any selective 




Chapter 4 – In this chapter we demonstrate the utility of a micro-nano scale biosensing platform 
in enabling personalized medicine for patient care. We used an electrical chip with 1024 X 1024 
array of Ion Sensitive Field Effect Transistor (ISFET) based molecular sensors for detection of 
nucleic acid molecules. The idea was to develop an electrical microarray for frequent measurement 
of various microRNA and other nucleic acid biomarkers for early detection of cancer and 
monitoring patient response to therapy at the bedside. Since, this chip allows label free electrical 
sensing of biomarkers, the need for lab scale fluorescence measurement equipment for the 
conventional microarray platforms is not needed. We used a PNA probe to specifically detect 
microRNA Let-7b which is a biomarker for lung, prostate and breast cancers. Due to the large 
number of transistors (>1 million) on the chip, we were able to get very good reliability and 
robustness in our results. 
 
 
1.2 Micro-nano scale platforms for personalized medicine in infectious 
diseases 
 
Chapter 5- Recent studies have shown that in an infection, pathogen specific factors can cause an 
increased risk of mortality and rapid detection of the genotypic data on the pathogens can help in 
early management of the disease9. In this chapter, we present a point-of-care platform for rapid 
identification of zika virus in human whole blood samples using a microfluidic platform and a 
smartphone-based imaging setup. The platform also allows detection of closely related Zika, 
Dengue (types 1 and 3) and Chikungunya virus infections from whole blood on the same pre-
printed microchip with high specificity and clinically relevant sensitivity using real-time reverse-
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transcription loop-mediated isothermal amplification (RT-LAMP).   
 






Figure 1.1| The effects of intratumor heterogeneity on the predictive value of biomarkers. 
Cancer diagnosis is based on core biopsies which may not be representative of all sub-clones 
(represented by different colored cells). The analysis on such biopsies guide treatment decisions. 
The treatment eliminates the dominant clones if successful, but then the clones resistant to the 
therapy (yellow) become dominant and drive the disease progression. Moreover, distant metastases 
may arise from cells disseminated early during tumor development and the clonal composition of 
metastatic tumors can be significantly different from their primary counterparts. Thus, treatments 
designed according to initial diagnostic samples would yield suboptimal results for metastatic 




Figure 1.2| Different pathways of personalized medicine in cancer. The workflow involves sequencing 
of patient biopsy samples to detect genetic alterations (top pathway) and use that data to decide the targeted 
drugs. But, most often there are no known FDA approved drugs for the alterations found and hence 
empirical testing of cancer drugs on patient derived tumor organoids must be performed (bottom pathway). 
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Chapter 2: Pixelated spatial gene expression analysis from 
tissue 
 
Here, we present a technique that performs on-chip picoliter real-time reverse transcriptase loop 
mediated isothermal amplification (RT-LAMP) reactions on a histological tissue section without 
any analyte purification while preserving the native spatial location of the nucleic acid molecules. 
We demonstrate this method by amplifying TOP2A messenger RNA (mRNA) in a prostate cancer 
xenograft with 100µm spatial resolution and by visualizing the variation in threshold time of 
amplification across the tissue.  The on-chip reaction was validated by mRNA fluorescence in situ 
hybridization (mFISH) from cells in the tissue section. The entire process, from tissue loading on 
microchip to results from RT-LAMP can be carried out in less than two hours. We anticipate that 
this technique with its ease of use, fast turnaround, and quantitative molecular outputs, would 
become an invaluable tissue analysis tool for researchers and clinicians in the biomedical arena. 
The work presented here in this chapter was published1. 
 
2.1 Introduction to spatial gene expression analysis and our platform 
 
The spatial localization of gene expression can unravel important insights into tissue 
heterogeneity, functionality and pathological transformations, but the ability to maintain this 
spatial information remains an enduring challenge in tissue sections routinely used for pathology. 
Amplification-based spatial gene expression analysis methods provide good sensitivity and 
specificity but decouple the analyte isolation and biochemical detection steps, making them low 
throughput and laborious2–4. Direct probe-based hybridization techniques such as single molecule 
FISH allow direct visualization of single RNA molecules in their native cellular context but are 
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not amenable to performing this on tissue section in a high throughout manner. In addition, off-
target binding of FISH probes and cellular auto-fluorescence can also become a limiting factor in 
imaging tissue samples5–8. Methods to perform spatially-mapped transcriptome analysis on a 
tissue section can identify multiple targets simultaneously but they must trade-off between the 
histologic reference and the quality of recovered biomaterials, as staining and manual 
identification are often needed9–12. These constraints limit the translation of the above methods 
into routine research and clinical practice.  
Here, we introduce a technique which improves upon these drawbacks by analyzing a starting 
sample of tissue cryosection and performing parallel picoliter RT-LAMP reactions with minimal 
sample processing. LAMP is an isothermal reaction which has been shown to be robust against 
factors in tissue that inhibit a PCR reaction13. LAMP uses 4-6 primers which identify 6-8 regions 
on the template for amplification which makes it more specific than PCR14.  For our work, we 
designed fingernail-sized silicon oxide-on-silicon chips with an array of 5,625 inverted pyramidal 
wells with ~175 pL volume each and having knife-like sharp distinct edges. As a tissue cryosection 
is loaded onto our chip, it is partitioned and transferred inside the wells in a process termed “tissue 
pixelation”. This process divides the solid tissue section into small tissue pixels and takes less than 
2 minutes. This is followed by tissue fixation (10 minutes), permeabilization (30 minutes), loading 
of wells with amplification reagents (2 minutes), and finally on-chip RT-LAMP reaction on a hot 
plate (45 minutes) (Figure 2.1).  The native spatial distribution of nucleic acid in tissue is 
preserved throughout the process.  
We demonstrate our technique with frozen sections of human prostate tissue xenografts grown in 
mice. Prostate cancer is the most commonly-diagnosed cancer in men and is the second leading 
cause of cancer death in men in the United States, accounting for more than 25,000 deaths in 
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201515. The molecular mechanisms fueling prostate cancer pathogenesis remain relatively 
unknown16–20; however, topoisomerase II alpha (TOP2A), a nuclear enzyme involved in 
chromosome condensation and chromatid separation, has been shown to be upregulated with 
increasing Gleason score and with hormone insensitivity in prostate carcinoma21. Tissue sections 
from LNCaP prostate cancer cell xenografts in mice were chosen to visualize the spatial variation 
of TOP2A mRNA using our technique. With a rapid turn-around time of less than 2 hours, starting 
from sample acquisition to RT-LAMP reaction, our technique can perform spatially mapped 
nucleic acid amplification testing in a typical analytical laboratory.  
 
 
2.2 Methods used in this study 
 
Cells and Xenografts: LNCaP prostate cancer cells were obtained from and verified by the 
American Type Culture Collection (ATCC). The cells were cultured per the recommended 
standard in a 37 °C humidified incubator with 5% CO2 atmosphere.  
LNCaP subcutaneous Xenografts were grown in immunocompromised nude mice (Jackson 
Laboratory). LNCaP cells were first incubated and grown to confluence. Then, these confluent 
cells were suspended in 10% Matrigel at a concentration of 2X107 cells/60μL and 60μL of this 
Matrigel-cell solution was injected subcutaneously into both flanks of the animal. The mice were 
then monitored daily for the presence of tumors. As soon as tumors were visible, volume 
measurements were taken using digital calipers twice a week, and tumor volumes were calculated 
using the formula volume=(length*width^2)/2. Once tumors reached 50,000 mm^3 in volume, the 
mice were sacrificed by overdosing with isofluorane anesthesia, after which the tumors were 
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immediately excised and divided to be placed in optimal cutting temperature compound (OCT), 
or 4%PFA. 
 
Primer Sequences: All primer sequences for the RT-LAMP and RT-PCR reactions were 
synthesized by Integrated DNA Technology (IDT) and are listed in Table 2.1.  Primerexplorerv4 
(https://primerexplorer.jp/e/) was used for designing the RT-LAMP primers for TOP2A mRNA. 
The cDNA sequence for TOP2A was obtained from NCBI database using NCBI Reference 
Sequence: NM_001067.3. https://www.ncbi.nlm.nih.gov/nuccore/NM_001067.3  
 
Off-chip reactions: RT-LAMP assay was designed to target the Topoisomerase II alpha (TOP2A) 
mRNA. The RT-LAMP assay comprised of the following components: 1x final concentration of 
the isothermal amplification buffer (New England Biolabs), 1.4mmol/L each of deoxy-
ribonucleoside triphosphates (dNTPs), 10mmol/L of MgSO4 (New England Biolabs), and 0.4 
mol/L of Betaine (Sigma-Aldrich). These components were prepared in bulk and stored at –20 °C 
between experiments. In addition to the buffer components, 1 μL of primer mix consisting of 0.2 
μM of F3 and B3, 1.6 μM FIP and BIP, and 0.8 μM of LoopF and LoopB, 0.64 U/μL Bst 2.0 
WarmStart DNA Polymerase (New England Biolabs), 0.08 U/μL AMV reverse transcriptase (New 
England Biolabs), and 1× EvaGreen (Biotium), a double-stranded DNA (dsDNA) intercalating 
dye, was included in the reaction. 10 μL template of the appropriate concentration and 1.92 μL of 
DEPC-treated water (Invitrogen) was added to make the final reaction volume 25 μL.  
The RT-PCR reaction was carried out using the RNA UltraSense ™ One-Step Quantitative RT-
PCR System (Thermofisher) according the manufacturer’s instructions. A 50 μL reaction mix 
contained 2.5 µl of RNA UltraSense™ Enzyme Mix, 10 µl of RNA UltraSense™ 5X Reaction 
11 
 
Mix™, 0.5 µl of 10 µM forward primer (100 nM reaction concentration), 0.5 µl of 10 µM 
backward primer (100 nM reaction concentration), 1 µl  of SYBR Green dye (Thermofisher), and 
34.5 µl of template of the appropriate starting concentration. 
Template for the RT-LAMP reactions included either RNA extracted from LNCaP cells or LNCaP 
prostate xenograft tissues, or whole LNCaP cells spiked in the reaction mix. All RNA extractions 
were performed using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. 
All RT-LAMP and RT-PCR reactions consisted of non-template negative controls, the 
amplification of which indicated a contaminated test.  
All the off-chip LAMP tests were carried out in 0.2 mL PCR reaction tubes in an Eppendorf 
Mastercycler® realplex Real-Time PCR System. The tubes were incubated at 60 °C for 60 minutes 
in the thermocycler, and fluorescent data was recorded every 1 minute. The off-chip PCR tests 
were conducted on the same thermocycler but with the following protocol: RT incubation at 50 
°C for 50 minutes, 2 minutes DNA denaturation at 95 °C, and 50 cycles of thermocycling from 95 
°C (15 seconds) to 60 °C (30 seconds). Fluorescence data was recorded after each cycle of the 
reaction. Triplicates were done for each reaction.  
 
Chip Fabrication and Chip Silanization: Undoped silicon wafers (University Wafers) were 
piranha cleaned for 10 minutes and a 160nm of silicon oxide was thermally grown in a furnace at 
1150°C for 90 minutes. A 2 μm layer of positive photoresist AZ1518 (AZ Electronic Materials) 
was spin-coated on the unpolished side of the wafer and was soft-bake on a hot plate at 110 °C for 
8 minutes. The same process was repeated on the polished size of the wafer. The photoresist on 
the shiny side was patterned using an EVG 620 aligner with a high resolution transparency mask 
(FineLine Imaging). The wafer was then developed in AZ400K (AZ Electronics) to remove the 
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exposed regions for 1 minute. The unprotected silicon oxide was etched in 10:1 buffered oxide 
etchant (VWR) to reveal the underlying bare silicon. This was followed by stripping the wafer of 
photoresist in a Remover PG (MicroChem) at 70 °C for 30 minutes. The wafer was then 
anisotrpically etched in a TMAH bath (1:1 TMAH:DI) for 100mins at 80°C to etch inverted square 
pyramidal wells with sharp well edges. To passivate the chip, 125 nm of silicon oxide was 
thermally grown in a furnace at 1150°C for 90 minutes.  
To render a positive charge on well surfaces for tissue adhesion, silicon chips were silanized with 
functional groups using (3-Aminopropyl)triethoxysilane (APTES). The chips were dipped in a 
glass jar containing 0.2% APTES for 60 seconds. The chips were then dipped 5 times in a separate 
vessel containing distilled water. This step was repeated three more times with the water being 
replaced between each step. The silanized chips were stored in a desiccator, and were used within 
15 days of silanization.  
 
Tissue Pixelation, Fixation, and Proteinase K digestion: The frozen tissue was cryo-sectioned 
at a thickness of 7 µm onto the center of the microchip and stored at -20 ˚C. Once ready for use, 
the tissue was taken out of the -20 ˚C freezer and dried immediately to minimize RNase activity 
within the tissue. A short heating step at 105˚C for 5 seconds was incorporated to ensure that the 
tissue is stabilized on the chip. A clean block of PDMS was then placed on top of the tissue and 
the whole PDMS-chip conjugate was centrifuged at 3000 rpm for 1 minute to press the tissue into 
the wells in a process known as tissue pixelation. The block of PDMS was discarded, and a second 
heating step at 105˚C for 7 seconds was carried out to ensure the tissue is firmly adhered and stable 
on the chip.  
A standard acetone fixation protocol was followed to fix the tissue onto the chip. The chip was 
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placed on a small glass petri dish filled with acetone and incubated at -20˚C for 8-9 minutes. After 
the incubation step, the chip underwent a series of wash steps. First, half of the acetone was 
discarded from the petri dish and an equal amount of cold PBS (Fisher Scientific) was poured into 
the petri dish to replace the acetone. The petri dish was shaken for 30 seconds and the step was 
repeated. The chip was then placed on a petri dish containing cold PBS and shaken for 2 minutes. 
This was followed by a rinse with DEPC-treated water at room temperature for one minute. The 
chip was then air-dried for 1 minute.  
The chip was placed on a petri dish with Proteinase K at a concentration of 7.5 µg/mL and 
incubated at 45 ˚C for 30 minutes. Once the digestion was complete, the Proteinase K was 
denatured by heating the chip at 95 ˚C for 90 seconds. The chip was washed with PBS for 10 
seconds and DEPC-treated water for 30 seconds to remove the residual Proteinase K.  
 
Bulk Loading and On-chip RT-LAMP reactions: A 25 µL reaction mix was prepared for a 
single on-chip test, and 10 µL of the reaction mix was pipetted onto the tissue/wells, and 
immediately coated with a layer of mineral oil. The chip was then placed in a petri dish covered 
with mineral oil and degassed for 5 minutes to remove any air bubbles. After degassing, the chip 
was dipped in mineral oil, and an air pressure is applied at an angle to shear off and remove excess 
reagents from top of the wells. The chip was then placed on a copper bowl and placed on a hotplate 
under a fluorescent microscope to perform the on-chip RT-LAMP reactions.  
The on-chip reactions were carried on a commercial hotplate at 65 ˚C for 60 minutes and imaged 
every 2 minutes under an Olympus BX51 fluorescence microscope with 3.6s exposure settings 




Amplification Data Analysis: The off-chip amplification and standard curves were plotted using 
a MATLAB script. The threshold time for each curve was taken as the time required for each 
curve to reach 20% of the maximum intensity. For on-chip reactions, the raw fluorescent intensity 
on-chip was extracted from each well and was plotted against time to generate the raw 
fluorescence curves. Each raw amplification curve was fitted to a sigmoidal curve using a four-
point parameter modeling (Figure 2.12). The following equation was used for the analysis:  
𝑓 = 𝑦0 +  
𝑎





Where f = fluorescence intensity, 𝑦0 = background fluorescence at time = 0 minutes, 𝑎 = difference 
between the initial and final fluorescent intensity, x = time point of analysis, 𝑥0 = inflection point 
of the curve, b = slope of the curve. The positive and negative wells were differentiated on the 
basis of the R2 value of the sigmoidal fit and the parameters  𝑎  and  𝑥0. The threshold time was 
taken as the point of inflection. Negative wells had a combination of low R2 value, low 𝑎 value, 
or a very high threshold time (𝑥0>50 mins). 
 
FT-IR Spectroscopic Imaging:  IR images were acquired using a Spotlight 400 (Perkin Elmer) 
IR imaging instrument at a spatial pixel size of 6.25um x 6.25um and a spectral resolution of 4cm-
1 at an under-sampling ratio of 2.  The spectral profile of a pixel was truncated to a spectral range 
of 4,000-720cm-1 for ease of data handling and classification. The sample was imaged in the 
reflection-absorption mode. Data were water vapor corrected and used for classification using the 
previously described Bayesian approach, metrics and algorithms for prostate tissue.  
IR imaging: FT-IR imaging was performed using a Perkin Elmer Spotlight 400 system. The 
spectra were collected using a mercury-cadmium-telluride (MCT) 16-element linear array detector 
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cooled with liquid nitrogen. The system is purged with N2 in order to reduce the interference of 
water vapor and CO2 infrared signal. The background was collected on a clear area of silicon chip 
at 4cm-1 resolution using 120 scans for each sample. The images were acquired in reflection mode 
with 6.25 μm x 6.25 μm pixel size and 4 cm-1 spectral resolution with 2cm-1 step size using a 
single interferometer scan with signal to noise ratio (SNR) exceeding 600:1 in all cases. Data was 
collected over the mid-infrared region and truncated for storage (750cm-1 to 4000cm-1). Since 
the samples were large, (smallest dimension being at least 500 μm for every section) and 
irregularly shaped, each image was acquired by breaking it down to 2 by 3 smaller rectangular 
regions and using raster scanning of these parts. Processing time for a square section of 1mm X 
1mm at 6.25 μm, starting with imaging and obtaining computational stain was about 2 hours. Each 
region was separately focused to avoid any error due to change in focus and the composite image 
was stitched back together using ENVI-IDL 4.8(Environment for Visualizing Images-Interactive 
Data Language).  
 
Bayesian inference-base method: Metrics were identified by the examination of spectra, S, by a 
trained spectroscopist from regions delineated by a trained pathologist. From the universal set of 
metrics, M = {m1, m2, ...mn}, an evaluation of pairwise error and incremental increase in 
classification accuracy for every class, C = {c1, c2,..., ci}, resulted in a subset of 2 metrics. These 
were further reduced to a set of 18 by leaving out one metric at a time and evaluating the resulting 
classification accuracy on validation array data. The classification process reported here consists 
of evaluating the maximum a posteriori probability for every class ci, pi(ci|M), for every metric 




Classification evaluation: As the threshold acceptance value determines an operating point for 
the algorithm, a systematic variation of the acceptance threshold can be used to carry out validation 
and statistical analyses of the classification results. 
 
TOP2A mRNA FISH Probe Design: FISH probes targeting human TOP2A mRNA 
(NM_001067.3, 3490 bp to 5753 bp) were designed using Stellaris® Probe Designer (version 4.2, 
LGC Biosearch Technologies, USA). Probe sequences with 85% or greater homology with mouse 
TOP2A mRNA complementary sequences were excluded. The resulting set of 36 mRNA FISH 
probes with 3’ Quasar 670 dye label was synthesized by LGC Biosearch Technologies. Probe 
sequences are listed in Table 2.2.   
 
Validation of TOP2A mRNA FISH on Cell Lines: Probe specificity was validated on TOP2A-
positive human cell lines (LNCaP and PC-3, generous gifts from Dr. Stephen J. Murphy, Mayo 
Clinic) and mouse cell lines as negative controls (3T3 and RAW 264.7, purchased from ATCC) 
following previously published procedures7 and protocols provided by the probe supplier. Briefly, 
1×105 cells were seeded on an 18 mm round #1 coverglass in each well of a 12-well cell culture 
plate. After adhering, cells were washed with phosphate buffered saline and fixed with 4% 
paraformaldehyde for 10 minutes at room temperature. Cells were then permeabilized with 70% 
(v/v) ethanol for 24 hours at 4°C. Ethanol was aspirated and Wash Buffer A (LGC Biosearch 
Technologies) was added. After incubation for 5 minutes at room temperature the coverglass was 
transferred face-down onto Parafilm with 100 μL of Hybridization Buffer (LGC Biosearch 
Technologies) containing probes. After incubation for 16 hours in the dark at 37°C in a sealed 
humidified chamber, the coverglass was washed with Wash Buffer A in the dark at 37°C for 30 
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minutes. Nuclei were counterstained with Hoechst 33342 (Thermofisher, USA) for 30 minutes. 
The coverglass was then washed with Wash Buffer B (LGC Biosearch Technologies) for 5 
minutes before mounting on slides containing Vectashield Mounting Medium, and sealed using 
nail polish. FISH probes and nuclei were imaged using a Leica SP8 UV/Visible Laser Confocal 
Microscope (Leica, Germany) with a 63× oil-immersion objective.  
 
TOP2A mRNA FISH on Prostate Tumor Tissue: Experimental procedures for FISH staining 
were reported previously22 and provided by the probe supplier. Tumor tissue sections were stored 
at –80°C and equilibrated to room temperature before use. The tissue-mounted slides were 
immersed in 4% paraformaldehyde fixation buffer for 10 minutes at room temperature and then 
treated in the same way as cell lines for mRNA FISH, with the exception that a 20× oil objective 
was used for image collection. 
 
mRNA FISH and Microchip Amplification Overlap Analysis: A pixelated mRNA FISH image 
with the same resolution as the spatial threshold map was created by generating a grid over the 
mRNA FISH image and taking the mean fluorescence intensity of the neighboring pixels within 
one unit or pixel of the grid. Since the placement of grid is done manually and is variable, we 
translated the grid in “x” and “y” directions to find the best overlap conditions between the 2 
techniques. Note that the splitting of an mRNA FISH signal into pixels can artificially increase 
the sensitivity of FISH during the pixelation process (1 fluorescent FISH signal can be split into 
maximum of 4 positive pixels depending on the grid line placement). This artefact is visible when 




IHC for TOP2A Protein. The immunostaining (IHC) experiment was performed at the Mayo 
Pathology Research Core and followed our previously published protocol23 with minor 
modifications. Briefly, the staining procedure used Leica Bond RX Stainer (Leica, Buffalo, IL). 
The frozen slides were pulled from -80 degrees and placed in a desiccator to dry overnight. The 
slides were fixed in 4% Paraformaldehyde for 10 minutes and then rinsed in PBS. The slides were 
loaded wet onto the stainer and the epitope retrieved on-line using Epitope Retrieval 2 (EDTA; 
Leica, Buffalo, IL) for 10 minutes. The primary antibody TopoIIA (Clone 3F6, Leica 
Microsystems) was diluted to 1:200 in Bond Diluent (Leica) and incubated for 15 minutes.  
The detection system used was Polymer Refine Detection System (Leica, Buffalo, IL). This 
system includes the hydrogen peroxidase block, secondary antibody polymer, DAB and 
Hematoxylin. Once completed, slides were removed from the stainer and rinsed for 5 minutes in 
tap water. Slides were dehydrated in increasing concentrations of ethyl alcohol and xylene prior 




2.3 TOP2A mRNA RT-LAMP in a thermocycler 
The first step towards our goal was to develop and characterize a sensitive and specific RT-LAMP 
reaction for TOP2A mRNA. We designed a new RT-LAMP reaction for amplifying TOP2A 
mRNA using 6 sequence specific primers (primer sequences provided in Table 2.1. 
To characterize our assay, RT-LAMP experiments using purified total RNA from xenograft tissue 
sections and cultured LNCaP cells were performed in a commercial thermocycler and compared 
with RT-PCR reactions performed using previously published primers with same RNA 
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concentrations24. Figure 2.2a and Figure 2.8 show the amplification curves and the standard 
curve for RT-LAMP reactions from purified RNA from LNCaP cells and tissue xenograft, 
respectively. A good linear fit for the standard curves was obtained for both reactions (R2= 0.93 
and 0.98 for total RNA from cells and tissue, respectively). Figure 2.2b shows the amplification 
and standard curves for TOP2A qRT-PCR reaction with the same starting RNA as in RT-LAMP. 
TOP2A RT-LAMP was found to be at least one order of magnitude more sensitive than the 
corresponding RT-PCR reaction with detection down to a quantity of total RNA equivalent to that 
of a single cell (in 25uL tube-based reactions). 
Next, to demonstrate the robustness of our RT-LAMP reaction, we spiked 1 to 100 LNCaP cells 
directly in a 25μl reaction tube using hemocytometer counting, and performed RT-LAMP. Figure 
2.2c shows the amplification fluorescence curves and standard curve for this experiment. Reaction 
with a single cell could be reliably amplified even in the presence of cell lysate. As seen from 
Figure 2.2a and Figure 2.2c, the amplification reaction works better for 100 cells spiked directly 
into the reaction as compared to purified RNA from 100 cells. We believe that this is due to the 
inefficiency of the RNA purification process. As will be shown in later sections, in our on-chip 
experiments on prostate cancer xenograft tissue, we find that the tissue debris remains attached to 
the bottom of the wells and hence does not interfere with the amplification reaction in the solution. 
This may have contributed to minimizing the effect of tissue contaminants in the assay.  
 
 
2.4 Tissue pixelation and bulk picoliter reagent loading 
To perform the RT-LAMP reaction on a microchip from tissue samples, we developed two unique 
preparatory steps:  
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Tissue pixelation- A continuous tissue cryosection in the shape of a disc (7um thick) was 
partitioned into small tissue “pixels” and placed into the corresponding microwells. This was done 
by applying a centrifugal force on the tissue disc via a flexible cured polydimethylsiloxane 
(PDMS) block, using centrifugation in a standard centrifuge (1min@ 1500g force). When the 
flexible PDMS pushes its way into the wells under centrifugal forces, it shears and partitions the 
tissue via the sharp well edges. Supplementary Figs. 1a-d show images from the characterization 
of our chip by scanning electron microscopy (SEM) , which demonstrate the sharp well edges. 
The tissue sticks to the well surface which was pre-silanized ((3-Aminopropyl)triethoxysilane or 
APTES), while the PDMS layer restores back to its original shape in the absence of force, as 
shown in the Figures 2.1d-f. Characterization of this process using SEM and fluorescence imaging 
for nuclei after DAPI staining is shown in Figures 2.3a-f. The well edges can be clearly visualized 
as dark lines in the DAPI stained fluorescent images. These data show that the tissue is completely 
inside the wells after the pixelation step and the tissue partitioning into pixels is complete, allowing 
for independent RT-LAMP reaction from tissue in each well. The 2-D tissue distribution is 
maintained throughout the process. Figure 2.9 shows additional SEM images of tissue pixelation 
for a rat heart tissue section, demonstrating that the process works with other tissue types. 
Bulk picoliter reagent loading- To fill the tissue loaded wells with less than 175pL of reagents 
per well, we developed a capillary action-based instrument-free loading technique. 5µL of 
reagents were pipetted on the chip and then the chip was immediately immersed in mineral oil. As 
mineral oil has a lower density than the water based reagents, it stays on top of the reagent-filled 
wells. With mineral oil acting as an envelope, excess reagents were sheared away using air 
pressure while capillary forces retained fluid only inside the wells. The process was characterized 
using fluorescent rhodamine dye. Figures 2.3g-h show well edges as dark lines indicating that 
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they are above the fluid level and that there is no cross-talk between adjacent wells. 98.2% of the 
wells were found to be fully filled (fluorescence intensity greater than 22 a.u), and partially filled 
wells were found only near the chip borders. Figure 2.7e-f shows the complete chip data for this 
process. The above two processes ensure independent picoliter RT-LAMP reactions in each well 
starting from a tissue sample. 
 
 
2.5 Real-time microchip RT-LAMP 
Before performing the real-time microchip RT-LAMP reaction, the pixelated tissue was fixed 
using acetone for 10 minutes at room temperature to prevent RNA degradation25. Following this, 
the tissue was treated with proteinase K (7.5 mg/ml for 30 mins), which digested the cell 
membrane proteins making the cells permeable to polymerase and reverse transcriptase enzymes.4 
This allowed RT-LAMP reagents to penetrate the cells and carry out amplification. As opposed to 
lysing the whole tissue in which scenario the tissue debris would have been completely mixed 
with the overlying solution in wells, using proteinase K digestion to expose the target analyte 
inside the tissue prevents the tissue contaminants from inhibiting RT-LAMP reaction. The 
amplification reagents were loaded using the previously described technique (bulk picoliter 
reagent loading) and the amplification was performed on a hot plate at 65 C. Imaging was done 
every 2 minutes using a 5X objective and TRITC filter in an Olympus BX51 fluorescence 
microscope. The on-chip amplification reaction was completed in 36 minutes and the progressive 
product accumulation in each well was visualized as proportional increase in the fluorescence in 
the corresponding well. The real-time fluorescence curves were used to calculate the threshold 
times for each well. Figures 2.4a-c show the fluorescence images at different time points, the 
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differential spatial fluorescence bar graphs, and the spatial threshold times, respectively. Notably, 
fluorescence data at the tissue margins were reliable amplification signals indicating robust 
measurements even at the tissue boundaries. Figure 2.4d shows the raw fluorescence data over 
time for a row of wells. A sigmoidal curve fitting was performed on the raw fluorescence curves 
from all the imaged wells and threshold time was calculated as shown in Figure 2.10e-f. 
Fluorescence curves from all the imaged wells are shown in Figure 2.4e after the fitting analysis. 
Analyzing regions close to the tissue boundary showed that the tissue boundary was maintained 
during the reaction suggesting that there was no crosstalk between adjacent wells and our rapid 
tissue pixelation and reagent loading technique indeed isolated each well (Figure 2.10a-d). The 
regions without any tissue showed no non-specific amplification. To demonstrate the scalability 
of our technology, we also performed similar on-chip reactions from tissue on two different well 
sizes of 300um and 500um. The results are shown in Figures 2.11-2.12. To further ensure that the 
signal observed was not due to spurious amplification, two negative controls, one with no primers 
in the reaction mix and other with RNase A (100µg/ml for 1hr) treated tissue were performed and 
no amplification was observed for either (Figure 2.13).  
As a final specificity test of the on-chip assay, we loaded cancer and non-cancer (mouse skeletal 
muscle tissue) tissue on the same chip and performing the RT-LAMP reaction. Figure 2.5 shows 
the fluorescence images at different time points, the differential spatial fluorescence bar graphs 
and the spatial threshold time analysis, respectively. Figures 2.5d and 2.5e show the raw 
fluorescence data for a row of wells and the amplification plots after curve fitting analysis, 




2.6 Fourier transform infrared imaging (FTIR) control 
To validate RT-LAMP based on the expression of TOP2A in different cell types (whether cancer 
epithelium or stroma), we performed label-free  FTIR imaging on the same section prior to 
amplification. In this setting, only cancer epithelium are expected to express TOP2A. FTIR 
provides a tissue-level view of the sample without the use of dyes or other reagents that are known 
to degrade RNA26,27. Furthermore, this technique has been previously used to provide label-free 
histology of prostate tissue with over 98% accuracy in determining cell types28–30. While IR 
imaging is usually performed on specialized substrates, here we made a small modification to 
make it compatible with our silicon microchips. As shown in Figure 14, a pixelated and fixed 
prostate cancer tissue section was imaged by FTIR spectroscopy before performing the RT-
LAMP. Figure 15 shows the process flow with FTIR control on the same section. Figure 16a-b  
show the bright-field image of the entire chip with tissue and the IR absorbance based 
classification of the tissue section into cancerous or epithelial (red) and non-cancerous or stromal 
(blue) regions. Figure 16c-g shows the end-point fluorescence image at the 36th minute for RT-
LAMP on the same chip, differential spatial fluorescence bar graphs, spatial threshold times, raw 
fluorescence curves for a column and all fluorescence curves for this experiment, respectively. 
The results clearly demonstrate that only cancerous regions amplified. To visualize the spatial 
heterogeneity in TOP2A mRNA across the tissue, we plotted the fraction of cancerous tissue per 
well (color bar) against spatially mapped threshold times to create a 4-dimensional plot (Figure 
16). Taking a given fraction of cancerous tissue per well as a reference for the starting sample 
amount in wells, the heterogeneity in TOP2A expression is evident as variation in threshold times 
in those wells as seen in Figure 16i. It can be observed that wells with none to negligible fraction 
of cancerous tissue (dark red) either don’t amplify or have very high threshold times, whereas 
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regions with high fraction of cancerous tissue (yellow) tend to show lower threshold times. Figure 
17 shows a repeat experiment with FTIR. 
  
2.7 Comparison with mRNA fluorescence in situ hybridization 
For further validation, we performed mRNA fluorescence in situ hybridization (FISH) and 
microchip spatial amplification on adjacent tissue sections. FISH probes for human TOP2A 
mRNA were confirmed to specifically stain human prostate cancer cells (PC3, LNCaP) and not 
stain mouse fibroblast or muscle cell lines (3T3, RAW 264.7) which do not express Top2A 
(Figure 18). The probe sequences are provided in Table 2.2. Figure 2.6a shows baseline 
subtracted fluorescence images for the microchip amplification at three different time points, 
demonstrating an increase in fluorescence over time and Figure 2.6b shows the spatial threshold 
time analysis, reflecting variations in Top2A mRNA across the tissue. Figure 2.6c shows confocal 
fluorescence micrographs of nuclei (blue) and TOP2A mRNA FISH (red). The TOP2A mRNA 
FISH micrograph was then pixelated at the same spatial resolution as the spatial threshold time 
maps and displayed in Figure 2.6d. Figure 19 shows an independent repeat experiment similar to 
the above. At 36-minute reaction times, the detection sensitivity of the RT-LAMP was compatible 
with mFISH (Figure 20). However, our spatial RT-LAMP had a distinct advantage over mFISH 
in that it provided quantitative expression values spanning over 4 orders of magnitude in only 2 
hours (including the amplification time). This turnaround time compared very favorably against 
the over 2 days required to perform the mFISH experiments, and that is without taking into account 
the considerable time that was required to capture and process mFISH images. These important 





2.8 Comparison with Immunohistochemistry (IHC) for TOP2A protein 
As another validation, we compared the TOP2A mRNA expression by RT-LAMP and protein 
expression by immunostaining (IHC) on adjacent tissue sections. Figure 21 shows the threshold 
time maps with the IHC images and their overlap analysis. As can be seen in the Figures, the 
spatial patterns for the TOP2A mRNA and protein expression are highly concordant.   
 
 
2.9 Chapter summary 
The technique presented here can be tuned to perform quantitative spatially-mapped nucleic acid 
analysis of any tissue sample type on a simple hot plate and a fluorescence reader. It can also be 
integrated into a completely portable setup using a smartphone and in-built heater making the 
technique accessible even to labs without a microscope13. Our technique allows analysis of small-
to-large tissue regions without any cross-talk between individual tissue pixels. The tissue 
pixelation and bulk picoliter reagent loading were easy-to-perform steps that take only 1-2 
minutes. This is important considering that commercial solutions for spotting arrays of 
nanodroplets cannot spot picoliters of volume in close spacing, have large dead volumes and suffer 
from long sample loading times (serial loading of 5000 wells would take several hours)31,32. Our 
technique can be scaled to fill larger arrays with millions of wells using the same principle in a 
matter of minutes. Both, the size of our chip and the spatial dimension of our wells can be tuned 
to meet sample size and spatial resolution requirements and we demonstrate this by showing on-
chip amplification for 300 and 500µm wells apart from the 100µm wells. We expect the same 
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should be possible for smaller well sizes, in which case we would make the wells deeper in order 
to keep similar reaction volume and kinetics as in the 100µm wells. Our technique, which can be 
easily performed in routine practice, has many important clinical and biological applications such 
as understanding tumor heterogeneity, predicting patient outcomes, and post-operative 
characterization of surgical margins 33. As such, we predict that microchip amplification will find 


















2.10 Figures and Tables 
  
Figure 2.1 | Overall process flow schematic. a, LNCaP cells are injected into a mouse and prostate cancer xenograft 
obtained. b, Xenograft is resected and immediately frozen and embedded in optimal cutting temperature compound 
(OCT) c, A 7um tissue cryosection is loaded onto our microchip. d, A cured PDMS block is loaded on top of tissue-chip 
assembly. e-f, The PDMS shears and partitions the tissue into small pixels at sharp well edges and pushes them into wells 
under centripetal force in a standard centrifuge. The pixelated tissue adheres to the silanized (APTES) well surfaces and 
the PDMS is removed. We call this process “Tissue pixelation” (Time = 2 minutes). g, Post pixelation, the tissue is fixed 
with acetone (Time = 10 minutes). A proteinase K digestion is performed after this to create a pathway for amplification 
enzymes to reach the target nucleic acids inside cells. (Time = 30 minutes) h, RT-LAMP reagents are pipetted on chip in 
bulk (5ul). i, Compressed air is blown on it at an angle inside mineral oil. j, Excess reagents are sheared away and fluid 
only inside wells is retained due to capillary forces. In the above steps, picoliter volume RT-LAMP reagents 
(~175pL/well) are loaded onto the chip through a rapid instrument-free technique we call “bulk picoliter reagent loading”. 
(Time = 2 minutes) k, Quantitative gene expression is visualized through real-time imaging of the amplification reaction 
in each well performed using only a hot plate at 65°C and a fluorescence microscope. (Time = 45 minutes). Images 









Figure 2.2 | Off-chip RT-LAMP assay characterization. a, Amplification curves and standard 
curve of the TOP2A mRNA RT-LAMP with purified total RNA extracted from LNCaP cells. 104 
cells had 940 ng of purified total RNA per reaction as measured with nanodrop spectrophotometer. 
b, Amplification curves and standard curve of the RT-PCR assay for TOP2A mRNA performed using 
previously published primers24. Our RT-LAMP assay can detect TOP2A mRNA from a single cell 
in reaction tube, whereas the RT-PCR assay can detect mRNA from only up to 100 cells (~9.4 ng 
total RNA) in a reaction tube (25ul per reaction).  The amounts of RNA per reaction for each dilution 
was the same as in RT-LAMP (Figure 2a) to allow direct comparison. c, Amplification curves and 
standard curve of the TOP2A mRNA RT-LAMP assay with whole cells spiked directly into the 
reaction tubes. TOP2A down to a single cell could be reliable amplified. All the reactions had 3 






















Figure 2.3 | Tissue pixelation and Bulk picoliter reagent loading characterization. a-d, SEM characterization 
after tissue pixelation. Tissue partitioning and division into small pixels can be clearly visualized as tissue seen 
inside the wells. The blue box in Figure 3a is shown in Figure 3b and the blue box in Figure 3b is shown in Figures 
3c and 3d. (scale bar: a-200um; b-50um; c,d -20um)  e-f, DAPI-fluorescence imaging of the same pixelated tissue 
showing nuclei inside the well boundaries. Figure 3f shows the region in yellow box in Figure 3e. (scale bar: e-
200um; f-50um)   g-h, Characterization after bulk picoliter reagent loading in tissue loaded wells. Fluorescent 
rhodamine dye was filled in the wells for characterization of cross-over across wells. Figure 3g shows the low 
magnification image of dye filled tissue (*) and no-tissue (**) regions and Figure 3h shows the high magnification 
image of a dye filled region (shown in yellow box in Figure 3g) with tissue. Well edges are seen as dark lines 
showing that they are above the fluid level and there is no overflow between adjacent wells. Partially filled wells 
indicated by a lower fluorescence were a small fraction of total wells on chip and confined to the chip boundaries 


























Figure 2.4 | On-chip RT-LAMP for TOP2A mRNA. a, Raw fluorescence images of real-time RT-LAMP with 
tissue on chip at four different time points. (*Tissue, **No Tissue). (scale bar: 200um)    b, Fluorescence bar 
graphs of the raw images showing a differential increase in fluorescence over time. The gain in fluorescence over 
time is calculated taking time= 0 image (initial) as the reference. c, Spatial threshold analysis showing the spatially 
mapped threshold times. Note that the tissue boundaries are maintained throughout the reaction. Each pixel is 
100um*100um.   d, Raw amplification curves of a row marked in red in “c” showing positive and negative wells. 

















Figure 2.5| On-chip RT-LAMP: Cancer vs non-cancer control. a, Raw fluorescence images of real-time RT-
LAMP with prostate cancer tissue on right and non-cancer (mouse skeletal muscle) tissue on left of chip at four 
different time points (*Non-cancer, **Cancer). (scale bar: 200um) b, Fluorescence bar graphs of the raw images 
showing a differential increase in fluorescence over time. The gain in fluorescence over time is calculated taking 
time= 0 image (initial) as the reference. Note the amplification occurring only for the cancerous tissue. c, Spatial 
threshold analysis showing the spatially mapped threshold times. Each pixel is 100um*100um. d, Raw 
amplification curves of a row showing positive and negative wells marked in red in “c”. e, Fluorescence curves 














Figure 2.6 | On-chip RT-LAMP with mRNA FISH on serial sections. a, Baseline-subtracted fluorescence images 
of real-time RT-LAMP with tissue on chip at three different time points showing the increase in fluorescence over 
time. (scale bar: 200um)  b, Spatial threshold analysis showing the spatially mapped threshold times. No 
amplification was observed till 36 minutes. c, DAPI (blue) and TOP2A mRNA FISH (red) images of the consecutive 
section showing spatial heterogeneity in TOP2A mRNA expression. (scale bar: 200um)  d, Pixelated intensity map 
of mRNA FISH fluorescence. The spatial pattern of TOP2A expression is similar between the two assay types. For 





Figure 2.7 | Chip and bulk loading characterization. a, Optical image of the chip beside a quarter. 
The dark region in the chip is the array of microwells. b, SEM image of the wells. c, Surface 
profilometer measurement of fabricated silicon oxide micro wells showing the depth of the wells. d, 
SEM image of the sharp well edge shown as red box in image b. The edge width is close to 1μm. e, 
Tiled fluorescent image of the complete chip showing filling distribution of the wells using Rhodamine 
dye (*no tissue, **tissue). It can be seen that only a few wells at the chip border are partially filled. The 
well edges are dark and clearly visible indicating no cross-talk between adjacent wells. f, Histogram 
showing the well fluorescence distribution after filling. Note that lower fluorescence is attributed to 
partially filled wells (region 1) and higher fluorescence values are for wells without tissue (region 2). 
The wells with fluorescence lower than 22 units were found to be partially filled and were present only 































Figure 2.8| RT-LAMP assay with purified RNA from tissue xenograft. Amplification curves (a) 
and standard curve (b) of the TOP2A mRNA RT-LAMP with purified total RNA extracted from 
tissue. 1x=2450ng (7um thick cryosection of PCa xenograft) of total RNA from purified RNA from 













Figure 2.9| SEM characterization of rat heart tissue pixelation. a-e, Tissue partitioning and division 
into small pixels can be clearly visualized as tissue inside the wells. The blue box in Supplementary 
Fig. 3a is shown in Supplementary Fig. 3b and the blue box in Supplementary Fig. 3c is shown in 




Figure 2.10 | Regional Image Analysis for Figure 3 in the main paper. a, Raw fluorescence image at time 
= 0 showing regions with and without tissue. b, Zoomed in processed image with numbered wells. The inset 
shows the entire processed image. c-d, Raw amplification curves for marked regions (blue and green) 
showing that the positive wells (with tissue) amplify while the adjacent negative wells do not. The tissue 
boundary remains preserved during the amplification reaction confirming that there is no cross talk between 
adjacent wells. e, 4 point parameter model used for the sigmoidal fitting of the raw amplification curves. The 
equation for the sigmoidal fit is given in the red box inside the figure and the corresponding parameters are 
represented in the data fit shown as an example. The threshold time was taken as the point of inflexion of 















Figure 2.11 | On-chip RT-LAMP with 300 µm well size. a, Raw fluorescence images of real-time RT-
LAMP with tissue on chip at four different time points. b, Corresponding 3D fluorescent bar graphs of the 
raw images showing a differential increase in fluorescence over time. The gain in fluorescence over time is 
calculated taking time= 0 image (initial) as the reference. c, Spatial threshold analysis showing the spatially 
mapped threshold times. Note that the tissue boundaries are maintained during reaction.  Threshold time=0 
refers to blanks. d, Amplification curves for all wells after curve fitting. e, Processed image with numbered 
wells. f-g, Raw amplification curves of the regions marked in blue and green in “e” showing the differences 






Figure 2.12 | On-chip RT-LAMP with 500 µm well size. a, Raw fluorescence images of real-time 
RT-LAMP with tissue on chip at four different time points. b, Corresponding 3D fluorescent bar 
graphs of the raw images showing a differential increase in fluorescence over time. The gain in 
fluorescence over time is calculated taking time= 0 image (initial) as the reference. c, Spatial 
threshold analysis showing the spatially mapped threshold times. Note that the tissue boundaries are 
maintained during reaction.  Threshold time=0 refers to blanks. d, Amplification curves for all wells 
after curve fitting. e, Processed image with numbered wells. f-g, Raw amplification curves of the 
regions marked in blue and green in “e” showing the differences in fluorescence between tissue and 





















Figure 2.13 | On-chip RT-LAMP negative controls. a-b, Raw fluorescence images of real-time 
RT-LAMP reaction with no primers added at three different time points and the corresponding 
amplification curves from all wells showing no amplification during the entire reaction period. c-d, 
Raw fluorescence images of real-time RT-LAMP reaction with RNase treated tissue at three different 
time points and the corresponding amplification curves from all wells showing no amplification 















Figure 2.14 | FT-IR spectral signature characterization. (a) Bright-field image of unstained tissue 
sample in which it is difficult to discern tumor from stroma. (b) IR imaging provides both spatial (x-y) and 
spectral data. (c) The data are reduced to biologically relevant metrics that characterize differences in cell 
types and can be used to recognize tissue histology without dyes or stains.  (d) Absorbance distributions 
of different cell types can be separated using machine learning methods (here a modified Bayesian 
approach). (e) Spectral characteristics of epithelial and stromal cells, showing subtle differences that can 
be directly detected by spectral changes. (f) Cellular type identified by machine learning using IR spectral 





Figure 2.15 | Overall process flow schematic with FTIR control on same section. a, LNCaP cells are 
injected into a mouse and prostate cancer xenograft obtained. b, Xenograft is resected and immediately 
frozen and embedded in optimal cutting temperature compound (OCT) c, A 7um tissue cryosection is loaded 
onto our microchip. d, A cured PDMS block is loaded on top of tissue-chip assembly. e-f, The PDMS shears 
and partitions the tissue into small pixels at sharp well edges and pushes them into wells under centripetal 
force in a standard centrifuge. The pixelated tissue adheres to the silanized (APTES) well surfaces and the 
PDMS is removed. We call this process “Tissue pixelation” (Time = 2 minutes). g, Post pixelation, the 
tissue is fixed with acetone (Time = 10 minutes). After fixation, FTIR imaging is performed on the tissue. 
A proteinase K digestion is performed after this to create a pathway for amplification enzymes to reach the 
target nucleic acids inside cells. (Time = 30 minutes). h, RT-LAMP reagents are pipetted on chip in bulk 
(5ul). i, Compressed air is blown on it at an angle inside mineral oil. j, Excess reagents are sheared away 
and fluid only inside wells is retained due to capillary forces. In the above steps, picoliter volume RT-LAMP 
reagents (~175pL/well) are loaded onto the chip through a rapid instrument-free technique we call “bulk 
picoliter reagent loading”. (Time = 2 minutes) k, Quantitative gene expression is visualized through real-
time imaging of the amplification reaction in each well performed using only a hot plate at 65°C and a 
fluorescence microscope. (Time = 45 minutes). Images created by Janet Sinn-Hanlon, The 




 Figure 2.16 | RT-LAMP with FTIR control on same section, experiment 1. a, Bright-field image of the 
pixelated tissue fixed on chip. The region in yellow square is the region imaged real-time during RT-LAMP 
b, FT-IR spectroscopy of our region of interest with the FT-IR image of the whole tissue in the inset. The 
red colour denotes the cancerous regions (epithelial) and the blue colour indicates the non-cancerous 
(stromal) regions. (scale bar on the bottom right is 200um) c, End-point fluorescence image (t=36 mins) of 
the region of interest after the on-chip RT-LAMP. (scale bar on the bottom right is 200um)  d, 3D plots 
showing the spatial distribution of fluorescent intensity in the tissue during different times of the RT-LAMP 
reaction. e, Spatial map showing the threshold times for amplification across the imaged tissue region. f, 
Raw amplification curves from a single column of wells (marked in red in c) showing the clear distinction 
in fluorescence between positive and negative wells. g, Processed amplification curves from all the 784 
wells imaged real-time. A clear distinction between the positive and the negative wells is observed. h, The 
fraction of cancer tissue per well as indicated by the red portion of FT-IR image in b, and i, a 4-D plot 
combining the spatially mapped threshold times with the fraction of cancer tissue per well and showing 
heterogeneity in TOP2A expression across the imaged tissue region. It can be observed that wells with no 
to negligible fraction of cancerous tissue (dark red) either don’t amplify or have very high threshold times, 





Figure 2.17 | RT-LAMP with FTIR control on same section experiment 2. a, Bright-field image of the 
pixelated tissue fixed on chip. b, FT-IR spectroscopy of our region of interest with the FT-IR image of the whole 
tissue in the inset. The red colour denotes the cancerous regions (epithelial) and the blue colour indicates the non-
cancerous (stromal) regions. c, End-point fluorescence image (t=48mins) of the region of interest after the on-
chip RT-LAMP. d, 3D plots showing the spatial distribution of fluorescent intensity in the tissue during different 
times of the RT-LAMP reaction. e, Spatial map showing the threshold times for amplification across the imaged 
tissue region. f, Raw amplification curves from a single column of wells (marked in red in c) showing the clear 
distinction in fluorescence between positive and negative wells. g, Processed amplification curves from all the 
784 wells imaged real-time. A clear distinction between the positive and the negative wells is observed. h, The 
fraction of cancer tissue per well as indicated by the red portion of FT-IR image in b, and i, a 4-D plot combining 
the spatially mapped threshold times with the fraction of cancer tissue per well and showing heterogeneity in 
TOP2A expression across the imaged tissue region. It can be observed that wells with no to negligible fraction 


















Mouse cell lines Human cell lines 
Figure 2.18 | Specificity validation of TOP2A mRNA FISH in cultured cell lines. Fluorescence 
micrographs show nuclear stain (Hoechst; top row) and TOP2A mRNA FISH (Quasar 647; bottom 
row). a-b) TOP2A-negative mouse 3T3 fibroblasts and RAW 264.7 macrophages show no significant 
TOP2A mRNA FISH signal. c-d) TOP2A-positive human prostate cancer cell lines PC-3 and LNCaP 






















Figure 2.19 | On-chip RT-LAMP with mRNA FISH on serial sections experiment 2. a, Baseline-
subtracted fluorescence images of real-time RT-LAMP with tissue on chip at three different time points 
showing the increase in fluorescence over time. b, Spatial threshold analysis showing the spatially mapped 
threshold times. No amplification till 36 minutes was observed. c, DAPI (blue) and TOP2A mRNA FISH 
(red) images of the consecutive section showing spatial heterogeneity in TOP2A mRNA expression. d, 
Pixelated intensity map of mRNA FISH fluorescence. The spatial pattern of TOP2A expression is similar 

























Figure 2.20 | RT-LAMP - mRNA FISH overlap analysis. a, Spatial threshold map using RT-LAMP 
shown in Figure 6. b, pixelated mRNA FISH intensity map c, Spatial binary overlap maps of the on-
chip RT-LAMP with the mRNA FISH data. The binary overlap map shows pixels with (i) both RT-
LAMP and mRNA FISH signal (yellow), (ii) only RT-LAMP signal (green), (iii) only mRNA FISH 
signal (light blue), and (iv) neither RT-LAMP nor mRNA FISH signal (black). d, Bar-graph showing 
the different percentages of positive pixels with (i) RT-LAMP signal only (green), (ii) both mRNA FISH 
and RT-LAMP signal (yellow), and (iii) only mRNA FISH signal (light blue). The graph shows that the 









Figure 2.21 | Comparison of TOP2A mRNA expression through RT-LAMP with TOP2A IHC for 
adjacent sections. The RT-LAMP experiment is the same as shown in Figure 6 and IHC was performed on 
a serial section. a, Spatial threshold analysis from RT-LAMP. b, TOP2A IHC from adjacent section in the 
region of interest. c, Pixelated TOP2A IHC expression obtained from “b”. The spatial signatures observed in 
the IHC images is consistent with those observed in RT-LAMP spatial threshold map. d-e, Zoomed in image 
for IHC showing staining. f, Spatial binary overlap maps of the on-chip RT-LAMP with the IHC data. The 
binary overlap map shows pixels with (i) both RT-LAMP and IHC signal (yellow), (ii) only RT-LAMP signal 
(green), (iii) only IHC signal (light blue), and (iv) neither RT-LAMP nor IHC signal (black). g, Bar-graph 
showing the different percentages of positive pixels with (i) RT-LAMP signal only (green), (ii) both IHC and 
RT-LAMP signal (yellow), and (iii) only IHC signal (light blue). The graph shows that the two techniques 






Table 2.1: Primers 




F3: GTC GTG TCA GAC CTT GAA 
B3: TAG TTC CTT TTG GGG CAG 
FIP: TCT GGG AAA TGT GTA GCA GGA GGC TGA TGA TGT TAA GGG CA 
BIP: AAC CCA GTT CCT AAA AAG AAT GTG AGT GGA GGT GGA AGA CTG A 
Loop F GGC TTG AAG ACA GTG GTA CAC 
Loop B: CAG TGA AGA AGA CAG CAG CAA 
TOP2A RT-
PCR primers 
Forward: TGG CTG CCT CTG AGT CTG AA 
Reverse: AGT CTT CTG CAA TCC AGT CCT CTT 
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Chapter 3: Miniaturized three-dimensional hanging drop 
micro-cancer arrays for drug testing with direct microscopy 
 
Tumor microenvironment is increasingly recognized as a key contributor to cancer progression 
and resistance to therapy. Three dimensional cultures have been shown to produce in-vivo like 
culture conditions which can help them recapitulate morphological and cellular characteristics 
relevant to in-vivo tumor. Although several three-dimensional culture techniques currently exist 
to produce organoids, they do not allow real time microscopy-based characterizations and 
individual organoid tracking, or high-resolution confocal analysis directly on the platform. Here, 
we introduce a ‘Nano hanging drop culture’ where individual nano-litre sized (10.8nL) hanging 
droplets are held by capillary forces inside inverted silicon oxide-on-silicon micro-wells in oil. 
Organoid formation happens in less than 1 day due to increased cell-cell interactions within the 
nano-droplet and without the need for any specific medium or matrices that can put selective 
pressure and bias tumor evolution during culture. Nano hanging drop organoids grown from 
human glioblastoma cell line and patient derived xenograft cells showed similar protein expression 
profiles to those observed in vivo in human tumor xenografts. Using both glioblastoma organoids 
and patient derived cell organoids, we also demonstrate the feasibility of drug testing directly on 
chip with real time microscopy-based monitoring of organoids for response to drug with days. 
Taken together, these results indicate the broad applications of our nano-sized hanging drop in 
various biomedical applications such as drug discovery, tissue engineering, and stem cell research.  
  
 
3.1 Introduction to 3D culture and our platform 
  
Molecular analysis in oncology has revealed the genomic complexity in cancer and underscored 
the need to target the unique alterations in the specific patient’s tumor. Knowledge of driver 
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mutations in a specific patient is crucial but genomic analysis alone fails to identify effective drugs 
or drug combinations in a significant number of cases1. Patients don’t always respond to therapy 
even when targetable genomic alterations are identified1. This is where strategies to confirm 
therapeutic efficacy of drugs would be beneficial. Towards this goal, three-dimensional (3D) 
culture systems offer the unique opportunity to culture cells in an environment that closely mimics 
native tumors and these interactions cause the 3D-cultured cells to acquire morphological and 
cellular characteristics relevant to in vivo tumors2,3. This is not possible in cell cultures in 2D 
monolayers and much work has been done to elucidate the significant differences in cellular 
morphology, behavior and molecular signaling between the classic cell monolayer approaches and 
analogous 3D cultures4.  
Although several 3D culture techniques deploying protein-based or synthetic polymer-based gel 
environments2, rotation-based bioreactors2, magnetic levitation11 and hanging drop techniques13,14 
exist but their broad practical application has been limited due to several reasons4. Matrix and 
hydrogel-based techniques often introduce unpredictable cell-polymer interactions which can 
influence and bias downstream applications of the organoids4. Aggregation techniques such as 
using magnetic levitation using nanoparticles to cause spheroid formation can only form a limited 
number of spheroids and requires cells to be pre-treated with magnetic beads which are expensive 
and can be toxic at high concentrations2. A special consideration is that all proliferative models of 
drug testing, including 2D, 3D organoids, and patient-derived xenograft models, are subject to 
selective pressure and tumor evolution5,6. Since the tumor microenvironment is increasingly 
recognized as a key contributor to cancer progression and resistance to therapy, removing selective 
pressure by optimizing culture conditions to maintain the tumor microenvironment are essential 
for accurate prediction of response to treatment, including immunotherapies. Ideally suited for this, 
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is the hanging drop technique where inverted droplets containing cells held by capillary forces 
form tumor spheroids and commercial hanging drop plates in 96 and 384 well formats are now 
available7–9. However, the current technology for performing hanging drop cultures is very 
laborious and low throughput and requires the disruption of culture conditions and transfer of 
formed spheroids into a secondary plate for end-point only analysis. Moreover, the current 
technique is not compatible with direct microscopy-based characterizations and also suffers from 
elevated osmolarity caused by evaporation of media from the droplets2.   
To address these challenges, we introduce a high throughput silicon micro-well based miniaturized 
array platform for inverted hanging drop 3D culture where the individual droplets with cells are 
held by capillary forces in a micro-well. This miniaturized and optimized culture conditions allow 
for a single cell seeding step to produce an array of hundreds to thousands of uniform tumor 
organoids which can be easily characterized in real-time through upright fluorescence microscopy 
for tumor spheroid formation, cell death and other processes. We demonstrate this technique with 
LN229 Human Glioblastoma cells and patient derived xenograft (PDX) Glioblastoma cells. As an 
application of our platform we show direct drug testing on LN229 and PDX glioblastoma tumor 
organoids formed on our platform with real-time optical microscopy-based characterization.  
 
3.2 Methods  
 
Off Chip Culture 
The LN 229 cells were cultured in the Dulbecco Modified Eagle Medium without sodium pyruvate 
(Gibco) including 10 % (v v-1) fetal bovine serum (ThermoFisher), 1 % (v v-1) non-essential amino 
acids (ThermoFisher), and 2 mM L-glutamine (ThermoFisher). After getting a 70-80 % of cell 
confluence, they were trypsinized with 0.25 % (w v-1) Trypsin 0.53 % (w v-1) EDTA solution 
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(Gibco) and loaded to chips. For the PDX cells, 1 % of penicillin-streptomycin (Lonza) was added 
to the media for LN 229 cell culture. The cells were cultured for two days after thawing the PDX 
from liquid Nitrogen tank to get the estimated counts and then loaded on to the chips.  
 
Chip Fabrication 
The oxidized silicon chip (10mm x 10mm) hasa microarray of wells (each 300um x 300um) with 
a depth of 120um. A 4-in. <100> silicon wafer (UniversityWafer, South Boston, MA) with one 
side polished was thoroughly cleaned and used as the substrate in the photolithography process. 
The wafer was dehydrated on a heating plate at 140°C for 2 min and cooled for 30 sec before 
loading into a Molecular Vapor Deposition (Applied MicroStructures, San Jose, CA). A single 
layer of Hexamethyldisilizane was deposited under low pressure to the polished side of the wafer, 
increasing the hydrophobicity of the wafer surface. After the deposition, the wafer was unloaded 
and dehydrated on an aluminum hot plate at 110°C for 2 min and cooled for 30 sec. Thereafter, 
positive photoresist SPR 220 (MicroChem, Newton,MA) was spin-coated on the polished side of 
the wafer to form a 4.5μm covering layer, followed by a soft-bake at 60°C for 2 min and 110°C 
for 1 min. The photoresist was then exposed with an i-line (365 nm) mask aligner (EVG 620) in a 
hard contact with an expose dose of 210 J/cm2. The exposed regions with the outline of the 
microarray pattern were subsequently removed by immersing the wafer in AZ 400K developer 
diluted 1:5 with deionized (DI) water for 45 seconds. For the anisotropic etching of the silicon 
substrate, a Bosch process reactive-ion etching (RIE) with alternating steps of SF6/O2 etching and 
C4F8 passivation was used to create a 120μm deep trench. After the Bosch process, the remaining 
photoresist was cleaned with acetone and isopropanol rinses. The photoresist was stripped with 
heated (100°C) PR Stripper 1165 for 10 minutes and sonicated for another 10 min, leaving the 
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bare silicon exposed. Finally, the wafer was thermally oxidized in a furnace (1150 °C) for 60 min 
to grow 137 nm SiO2 and subsequently scribed into individual chips.  
 
Cell Seeding on Chip 
To prepare for cell seeding, the chips were cleaned using a piranha etch to rid of any organic 
residues on the surface of the wells. About 45 minutes before use, the chips were rinsed with 
acetone and isopropanol, and dipped in ethanol (200 Proof) for 2 min. Thereafter, the chips were 
blow dried with nitrogen gas and kept in a covered petri dish. Before cell seeding, the chips were 
made hydrophilic through O2 plasma treatment at 300 W for 3 minutes. Thereafter, a cured PDMS 
polymer with a reservoir of a size according to the required number of exposed wells was attached 
to each chip.  
 
The total number of cells to be loaded on a single chip was equal to the product of the number of 
wells to be filled with cells (in the PDMS reservoir) and the number of cells needed per well 
(organoid size control).  
 
The total number of cells were extracted from the culture into a 1.7 mL tube and then centrifuged 
at 200g for 5 min so that all cells settle to the bottom of the tube. After aspirating the supernatant, 
the cells were washed with serum free media and centrifuged at 400g for 5 min. After, a PKH26 
Red Fluorescent Cell Linker Kit for general cell membrane labelling (Sigma-Aldrich) was 
prepared according to product instructions and mixed with the cells. To stop the PKH 26 Red 
Fluorescence staining, serum-free media was added to the cell and dye solution. The cells were 
again centrifuged at 400g for 5 minutes to bring all cells to the bottom of the tube and subsequently 
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the supernatant was discarded. CellTox Green Cytotoxicity Assay (Promega), a green dye required 
to determine cytotoxicity and compatible with real time imaging, was prepared according to 
product instructions (1:500 ratio of dye to media) in media with serum. This media and green dye 
solution were then added to the cell suspension in the total volume required to seed on to the chips. 
For PDX cells, the cell seeding process was the same, except all media used included 1% 
Penicillin-Streptomycin. 
 
The cells were then seeded on chip and centrifuged in a petri dish at 200g for 2 min. Immediately 
after, the chip was dipped in mineral oil, and an air pressure was applied to the chip to shear off 
the excess media from the top of the wells. This process is done to digitize or partition the chip 
and create individual disconnected wells with cells inside them. The shearing process can also be 
done with a mineral oil flow from top to bottom of the chip. The chip was then inverted in mineral 
oil to form inverted hanging nano droplets. These inverted chips were then incubated in 37°C, RH 
95% and 5% CO2. The cells were incubated for 9 days in this condition, taken out for 10 mins 
daily for imaging and drug loading on Day 3 after cell seeding. 
 
Organoid Imaging  
Real time imaging was done daily after seeding with an Olympus BX63 fluorescence microscope 
with a 10x objective (0.3 NA). Tiles of the area with organoids and Z-stacks of 10um slice 
thickness were taken of chips in brightfield, GFP and RFP fluorescence wavelengths. The CellTox 
green fluorescence dye was captured using the GFP fluorescence and the PKH Red dye was 





On Day 3 after cell seeding, the chips were loaded with drugs diluted to the desired concentration 
in media, except for the negative control chip in which only media was loaded. Media with serum 
was prepared with CellTox Green Cytotoxicity Assay as explained above. Media with serum for 
PDX cells included 1% Penicillin-Streptomycin. The drug stock of 10mM Dasatinib in 100% 
DMSO (obtained from Mayo clinic) was diluted in the media and dye solution to achieve the 
desired concentration of drug (10uM to 100pM). Compensating for the volume of media already 
in the wells, the concentration of the drug was increased. For example, if the cell culture had 100 
wells loaded with organoids, then the volume of media already present in the wells = volume of 1 
well * 100 = 10.8nL * 100 = 1080nL. During drug loading, if 50ul of media with drugs was added 
on this chip, then the final total volume = 50 + 1.08 uL = 51.08uL. So the concentration of the 
drugs in the 50ul of media added = (51.08/50)*X; where X is the desired final concentration. 
 
Before drug loading, the chips were first centrifuged at 200g for 5 minutes. Then, 10-50uL of the 
drugs/media solution was added in the cell area through the mineral oil layer on the chips. Density 
of the drugs/media is greater than density of mineral oil. Thus, the increased density allows the 
drugs/media to settle through the mineral oil and make contact with the wells. Hydrophilic media 
already inside the wells allow the drug to be spread throughout the area. The chips were then left 
upright for incubation at room temperature for 30 minutes. Thereafter, the chips were centrifuged 
again at 400g for 2 min. The chips were then dipped in mineral oil and the excess media and drugs 
were sheared off with a mineral oil flow.  The chips were then inverted in mineral oil and incubated 





Each of the images were converted to Tiff Series, in which a single tiff image of the series was of 
a single z-stack slice.  Autoquant X3 software was then used for 3D deconvolution of the 
brightfield, green, and red channels of these tiff series images. The 3D deconvolution algorithm 
utilizes multiple iterations to develop a theoretical point spread function for the fluorescent points 
for each image. The optical parameters for the deconvolution included pixel spacings of 1um x 
1um x 10um. The objective lens had a numerical aperture of 0.3. The emission wavelengths were 
508nm and 565nm for green channel (CellTox Dye), and red channel (PKH Red Dye), 
respectively. The resulting deconvolved images were then analyzed using Imaris (Bitplane) 
software. In this software, the green and red dye were used to track and calculate the dead cells 
and analyze the organoid volumes, respectively. This software utilizes algorithms to identify the 
local contrast in intensity to determine a threshold for color capture. The cell function was used to 
determine the green volume of the dead cells and the surface function was used to calculate the 
volume of the organoids. Volumetric analysis files were exported as excel files, which were used 
to map the cell death and organoid volumes in each well. A MATLAB script was created to extract 
the positional data from each of the cell information and volume information and finally the total 
volume of the organoid as well as the total cell death (green volume normalized with red volume) 
in each well was calculated. The results of each well were plotted against time in line graphs in 
Excel and box-and-whisker plots of the cell death were generated according to drug concentration 
in Excel as well. Maximum projections were also obtained from Imaris software.  
 
Confocal Imaging 
Samples were fixed in 4% (v v−1) of paraformaldehyde overnight in 4 °C then washed with PBS 
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three times and used 0.25% (v v−1) diluted Triton-X to permeabilize the organoid membrane for 
15 min. After washing with PBS, samples were blocked and stored in 1% (w v−1) bovine serum 
albumin (Sigma-Aldrich) at 4 °C overnight. The primary antibodies, rabbit N-Cadherin 
monoclonal antibody (ThermoFisher) and mouse mitochondria monoclonal antibody 
(ThermoFisher), were used to stain for cadherin and mitochondria, respectively, at a 1:50 dilution, 
then incubated overnight at 4 °C. Both primary antibodies are human specific. Samples were then 
washed three times before staining with secondary antibodies. AlexaFluor-568 anti-rabbit 
(ThermoFisher) and AlexaFluor-488 anti-mouse (ThermoFisher) were used to stain N-cadherin 
and mitochondria primary antibodies, respectively, and incubated overnight at 4 °C. DAPI 
(ThermoFisher) was used for staining of nucleus and incubated for 1 hour at room temperature. 
After washing with PBS three times, samples were mounted on the cover glasses by using ProLong 




3.3 Experimental design   
 
We fabricated an array of 900 cuboidal silicon wells with edge length of 300um and depth of 
120um. The silicon surface was oxidized after the formation of the wells. The entire chip is about 
the size of US 1 cent coin (Figure 1b). The spacing between each well was kept at 20um. Each 
individual well in this array will downstream act as an incubation chamber for a tumor spheroid. 
A detachable Polydimethylsiloxane (PDMS) well (or well array) was assembled on top of the 
silicon chip to select a subset of wells which can be customized to the number of tumor organoids 
required.  The temporary adhesion between the PDMS well and the chip surface forms a removable 
reservoir over the chip where the cell solution can be loaded and centrifuged.  Figure 3.1 shows 
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the platform design and schematic of cell seeding on chip protocol and a tile of LN229 tumor 
organoids after 1 day of culture on chip. We start with making the surface of the chips hydrophilic 
by exposing the chip to oxygen plasma for 3 minutes at 300 watts (Figure 3.1a(1)).  This step 
serves 2 roles. First, the hydrophilicity helps in homogenous cell seeding by allowing easy access 
of media and cell solution inside the wells, and second, it makes the chip surface and environment 
sterile for downstream culture. After making the chip hydrophilic, the cell solution is loaded in the 
PDMS reservoir and the cells centrifuged at 200g for 2 minutes. The centrifugation step brings 
down the cells into the underlying wells and loads the entire array in a single step (Figure 3.1a(2-
3)).   Once the cell loading is complete, the PDMS reservoir is removed and the individual micro-
wells are partitioned using mineral oil and shear force from air or oil as described in our work10 
(Figure 3.1a(4-5)). This step removes well-well connections and forms individual droplets in 
wells. Finally, the chip is kept inverted in mineral oil in cell culture chamber to create inverted 
hanging drops and this increases cell-cell interactions and causes tumor spheroid formation 
(Figure 3.1a(6)).  Since the volume of each well is ~ 10.8 nL, the mineral oil layer also serves as 
an evaporation barrier allowing culture for an extended period. It is important to note that no 
additional surface coatings or gel formulations which might put selective pressure on tumor 
evolution is required in our technique.  Figure 3.1c shows a microscope image of a high throughput 
culture after 1 day of culture post cell seeding.  
 
 
3.4 Cell culture on chip  
 
To demonstrate organoid growth and the possibility of varying the size of tumor organoids on our 
platform, we seeded varying concentrations of starting cell suspension on chip to get organoids 
from 300 to 1000 cells per well (starting cell numbers on day 0). A real time imaging compatible 
cell death indicator green dye (Celltox, Promega) was added to the media to indicate cell death 
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and a cell membrane staining red dye (PKH, Sigma Aldrich) was also included to quantify changes 
in tumor organoid volume with time. A tile and z stack were taken for the chip for each day of 
culture to volumetrically map the green and red volumes within a micro-well. Volumetric mapping 
for green and red dyes was performed on Imaris software and final individual well tracking was 
performed using MATLAB. Details of analyses are mentioned in the methods section of the 
chapter and Figure 3.8 shows the overall Imaris process flow with example images. The cell death 
for each tumor organoid was normalized to its own volume to account for well to well variations 
in cell numbers and was calculated by dividing the total green volume by the organoid volume in 
that same well. Figure 3.2 shows the box and whiskers plot (n=12) of tumor organoid volume and 
cell death for varying cell numbers per well over 3 days of culture for LN229 human glioblastoma 
cells. We found that 300 cells per well did not seem to aggregate as well as the other higher cell 
numbers per well. Note that for 1000 cells per well, the volume of organoid is ~4nL on day 1 
which is still less than 50% of the micro-well volume (10.8nL).  
To demonstrate the feasibility of culturing primary cells on our platform, next, we repeated the 
above experiments with patient derived xenograft (PDX) glioblastoma cells which were harvested 
from mice. Figure 3.3 shows the box and whiskers plot (n=12) of tumor organoid volume and cell 
death for varying PDX cell numbers cultured on chip for 3 days. Interestingly, for PDX cells, the 
300 cells per well scenario formed dense organoids as opposed to their cell line counterpart as 
compared to figure 3.2a and observed visually. Also, the PDX organoids seemed to have lower 
day 1 volumes for 700 (~1.5nL) and 1000 cells (~2nL) per well compared to their LN229 cell line 
counterparts (3.5nL and 3.75nL, respectively) which could be due to higher loss of PDX cells 
during pipetting in various steps. It is important to note that our technique can optically track 
individual wells for changes in cell death or organoid volume over time and can automatically 
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normalize for any variations in cell loading process. Figures 3.12- 3.13 shows individual traces of 
volume and cell death versus time for each organoid. 
 
3.5 Morphological and molecular characterization   
 
We also performed morphological analysis to reveal the integrity of these three-dimensional 
organoids using scanning electron microscope (Figure 3.9). It is important to note that the samples 
could be directly fixed and imaged on chip without the need for any extraction.  
We also characterized the tumor spheroids formed in our platform both structurally and 
molecularly to show their similarity with in vivo tumor characteristics and hence propose their 
utility as in vitro organoid models for drug screening in Glioblastoma. We cultured human 
glioblastoma cell (LN229) and PDX organoids on chip for 3 days and then imaged them using a 
high-resolution confocal microscope directly on chip. We evaluated the expression of N-cadherin, 
a transmembrane protein that mediates cell-cell contact through homotypic cell adhesion, and 
found that organoids formed on our platform showed N cadherin expression in the membrane, cell 
junctions and cytoplasm (Figure 3.4). This is consistent with previous findings which have shown 
differential N-cadherin expression in two-dimensional cultures which express N-Cadherin in the 
cytoplasm and nucleus but absent from membrane as opposed to the three-dimensional cultures 
and tumor xenografts, both of which express N-cadherin in membrane, cytoplasm and cell 
junctions11,12.  Figure 3.10a-b shows confocal images of LN229 tumor organoids with high N-
Cadherin expression in membrane, cytoplasm and cell junctions within 1 day of culture on-chip. 
Figure 3.10c-g shows a large confocal tile of an array of tumor organoids on chip and high-
resolution confocal analysis of individual tumor organoids. Figure 3.11 shows a confocal z-stack 
of a PDX organoid. These results demonstrate our platforms ability to perform high-throughput 
and high-resolution protein expression analysis to elucidate and study heterogeneity across the 
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cultured organoids on chip.    
It is important to note that the high-resolution confocal analysis presented in the above section was 
done directly on chip without the need to extract the organoids. This feature allows users to select 
and analyse specific organoids based on any user criteria and adds to the ability to track individual 
organoids over the entire course of analysis.  This can be very important when heterogeneity within 
the organoids formed from the same cell suspension can be expected. This tracking is not possible 
in techniques which require users to extract the organoids in bulk and analyse them downstream. 
This direct on chip characterization can be even more important for primary cell organoids which 
can be very fragile and break upon shear stress from pipetting and handling. This further illustrates 
the direct compatibility of our platform with several forms of high-resolution optical 
characterizations.  
 
3.6 Ability to harvest organoids from chip for off chip analysis  
 
Since our system is in an open format, we can easily harvest the formed organoids from our chip. 
To do this, the chip is first submerged in media to remove the residual oil layer from the top of the 
array. This can be done in a 12 well plate and ~1ml of media. Then, the organoids cane be removed 
directly by pipetting and aspirating the volume from above the chip. Once the organoids have been 
harvested, they can be used for any offchip analysis as needed. 
 
3.7 Application: Drug testing directly on chip  
 
We next evaluated the ability to do drug testing directly on our platform by taking real time 
measurements of response to drug as opposed to the current hanging drop method used to extract 
the formed tumor organoids and then performing an end-point only analysis in a separate well 
plate. We chose Dasatinib for performing the drug testing and it was introduced in our study after 
3 days of on chip culture. The process for introducing the drugs on chip was as follows. The chip 
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was kept upright inside mineral oil and centrifuged briefly to have the organoids settle at the 
bottom of the wells. Then, appropriate volume of media with drugs is loaded on chip through oil 
and allowed to incubate for 30 minutes in which time the drug diffuses into the wells containing 
organoids and the concentration becomes homogenous. The volume of drugs loaded depends on 
the number of organoids being cultured or wells filled with media on chip, which in turn, are 
defined by the size and numbers of PDMS reservoirs initially used for cell seeding. The volume 
of media with drugs added is usually 5 times the volume of total wells on chip previously filled 
and containing organoids. The concentration of loaded drug is increased by an appropriate factor 
to account for the media without drugs already present in wells to get the desired final drug 
concentration in the wells post diffusion. After 30 minutes of incubation, the chip is partitioned 
again using oil and inverted in oil for subsequent culture. Measurements for green and red 
fluorescence were taken daily using a wide field upright fluorescence microscope. It is important 
to note that this same process can be used to periodically change media on chip for long term 
organoid culture. 
Figure 3.5 shows the results of drug testing for LN229 cell organoids. Figure 3.5 a-g are alternate 
day maximum projection images for concentrations of 10uM (Fig 5a) down to 100pM (Fig 5f) and 
No drug control (Fig 5g) in descending order. Figures 3.5 h-f show the box and whiskers plots 
(n=12) of tumor organoid volume and normalized cell death. It can be observed that for higher 
concentrations of drugs (10uM, 1uM and 100nM), the cell death starts to increase as soon as 2 
days after culture with drugs (Day 5 overall and in the figure) compared to the no drug control and 
lower drug concentrations. Due to excessive cell death and destruction of organoids for these high 
drug concentrations, the entire well starts to appear green for days 7 to 9 and hence the overall 
green volume captured exceeds the organoid volume (red) and the normalization results in values 
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greater than 1. We also performed drug testing on PDX organoids and Figure 3.6 shows the results 
of drug testing. Figure 3.6 a-g are alternate day maximum projection images for concentrations 
10uM (Fig 6a) down to 100pM (Fig 6f) and No drug control (Figure 3.6g) in descending order. 
Figures 6h-f the box and whiskers plot (n=12) of tumor organoid volume and normalized cell 
death. Interestingly, the overall response to drugs in terms of normalized cell death was lower for 
PDX (<0.4) compared to cell line (>1) as the PDX organoids remained intact even for higher drug 
concentrations. Figures 3.14-3.15 show individual traces of volume and cell death as response to 
drug over time for each organoid for LN229 and PDX drug testing, respectively. Finally, Figure 
3.7 shows the IC50 curves for both the LN229 cell line and PDX organoid drug testing. The IC50 
value for LN229 organoids was found to be 95.9nM which is about 7 times higher than that of 
PDX, which was 13.8nM.  
 
3.8 Chapter summary  
 
We have described a novel miniaturized hanging drop three-dimensional culture platform which 
is high throughput and allows direct microscopy based optical characterizations. We demonstrated 
control of organoid size both for human glioblastoma cell line and PDX organoids, and the ability 
to perform real time fluorescence observations while tracking individual organoids directly on chip 
and thus eliminating the need for any organoid extractions. We also demonstrated compatibility of 
our culture with high resolution scanning electron microscopy and confocal microscopy directly 
on chip. The miniaturized hanging drop platform described here does not require a specific 
medium, matrices, specialized gels or nanoparticles, engineered scaffolds, or any form of synthetic 
surface coatings to form the organoids. This is especially useful when any of the above agents can 
be suspected of creating selective pressure and biasing tumor evolution during the organoid 
culture. This simple, scalable and customizable platform may be suitable for a broad range of 
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applications in drug discovery, regenerative medicine, stem cell research and biotechnology.  
 










Figure 3.1 | On-chip cell culture schematic and characterization. a, Overall process flow schematic. Chips are 
made hydrophilic through oxygen plasma at 300 W for 3 min. Prepared cell solution in media is loaded on chip into 
the PDMS reservoir and centrifuged at 200g for 2 min. Then, the chip is dipped in mineral oil and air pressure (or oil 
shear) is applied to shear off excess media and digitize the wells. Finally, the chip is inverted for 3D organoid 
formation. b, Optical image of the chip beside a quarter. The chip is an array of 900 microwells. The chips are 
assembled with a cured PDMS polymer with a reservoir of preferred diameter to select a subset(s) of wells to be 
loaded. A 4mm diameter and 8mm diameter PDMS reservoir is shown as an example. c, Organoid formation seen in 
each well 1 day after cell seeding. Depending on the reservoir diameter of the PDMS, high throughput organoid 
formation is possible with a single cell seeding step. Easy optical characterization with an upright microscope is 






Figure 3.2 | On-chip LN229 glioblastoma cell culture. a-d, Maximum projections of formed organoids in 12 well 
culture for days 1-3 post cell seeding of a 300 cells per well , b 500 cells per well, c 700 cells per well and d 1000 
cells per well. e, Box and whiskers plot of organoid volumes for each cell variation type for days 1-3 post cell seeding. 
The data encompasses volumes of organoids for the 12 wells (n=12) seen above for each condition. f, Box and 
whiskers plot of cell death (green volume normalized to red volume) for each cell variation type for days 1-3 post cell 
seeding. The data encompasses cell death data for the 12 wells (n=12) seen above for each condition. Each well has a 






Figure 3.3 | On-chip PDX culture a-d, Maximum projections of formed organoids in 12 well culture for days 1-3 
post cell seeding of a 300 cells per well , b 500 cells per well, c 700 cells per well and d 1000 cells per well. e, Box 
and whiskers plot of organoid volumes for each cell variation type for days 1-3 post cell seeding. The data encompasses 
volumes of organoids for the 12 wells (n=12) seen above for each condition. f, Box and whiskers plot of cell death 
(green volume normalized to red volume) for each cell variation type for days 1-3 post cell seeding. The data 
encompasses cell death data for the 12 wells (n=12) seen above for each condition. Each well has a side length of 





Figure 3.4 | Molecular characterization of LN229 and PDX organoids to assess in vivo similarity. Figures a-c 
show immunofluorescence detection of N-cadherin (red), DAPI nuclear staining (blue), and Human Mitochondria 
staining (green) in organoids formed with LN229 cells and patient derived xenograft.  a, Tile of 12 well culture of 
LN229 organoids image directly on chip. (scale bar: 100um)  b, Tile of 12 well culture of PDX organoids image 
directly on chip. (scale bar: 100um)  c, High resolution images of individual organoids for LN229 and PDX. (scale 







Figure 3.5 | On-chip LN229 drug testing. a-g, Maximum projections of 12 well cultures for days 1-9 post cell 
seeding (initial cell concentration: 500 cells/well). On Day 3 post imaging, Dasatanib was loaded onto the chips. Final 
concentrations of drug added were a 10uM, b 1uM, c 100nM, d 10nM, e 1nM, f 100pM, g Negative Control (only 
media and Celltox green dye was added). h, Box and whiskers plot of volumes of organoids from each drug 
concentration type for days 1-9 post cell seeding. The data encompasses volumes of organoids for the 12 wells (n=12) 
seen above for each condition. i, Box and whiskers plot of cell death (green volume normalized to red volume per 
well) from each drug concentration for days 1-9 post cell seeding. The data encompasses cell death data for the 12 





Figure 3.6 | On-chip PDX drug testing. a-g, Maximum projections of 12 well cultures for days 1-9 post cell seeding 
(initial cell concentration: 500 cells/well). On Day 3 post imaging, Dasatanib was loaded onto the chips. Final 
concentrations of drug added were a 10uM, b 1uM, c 100nM, d 10nM, e 1nM, f 100pM, g Negative Control (only 
media and Celltox green dye was added). h, Box and whiskers plot of volumes of organoids from each drug 
concentration type for days 1-9 post cell seeding. The data encompasses volumes of organoids for the 12 wells (n=12) 
seen above for each condition. i, Box and whiskers plot of cell death (green volume normalized to red volume per 
well) from each drug concentration for days 1-9 post cell seeding. The data encompasses cell death data for the 12 






Figure 3.7 | Hill plots of cell death response to Dasatinib drug for LN229 and PDX organoids. a, The IC50 for 
LN229 organoids is 95.9 nM.  b, The IC50 for PDX organoids is 13.8nM. Data shown in a and b are based on 12 well 






Figure 3.8 | Volumetric Analysis of Deconvolved images of 12 well organoids. Analysis flow starts with 
deconvolved images of tumor organoids being analyzed. Cellular death is mapped using green volume through local 
contrast thresholding and organoid volume is mapped using red volume surface mapping. Top and side views of 
process flow is seen.   
Map volume green Deconvolved image 
Map volume red 
TOP VIEW - Array  






Figure 3.9 | SEM characterization of Organoid formation. a-c, Complete organoid formation can be seen in each 
well. Each well has a side length of 300um (for scale). The red box in (a) is shown in b. (scale bar:100um) c, Cell 








Figure 3.10 | Confocal Images of Organoids. a-b, Confocal images of 3D organoid with LN 229 one day after cell 
seeding. Immunofluorescence detection of N-cadherin (red) and DAPI nuclear staining (blue). (scale bar: 20um) c, 
Large tile of uniform LN 229 organoids 3 days after cell seeding along with N-cadherin and DAPI staining, as well 
as human mitochondria staining (green). (scale bar: 200um) d-g, Single well confocal images of 4 different organoids 





Figure 3.11 | Confocal Z-Stack Images of PDX organoid after 3 days of culture on chip. a-f, Confocal z-stack 
image of PDX organoid three days after cell seeding. Distance between each z-stack slice is 10um. 
Immunofluorescence detection of N-cadherin (red), DAPI nuclear staining (blue), and human mitochondria staining 




Figure 3.12| LN 229 organoid volume and cell death tracking of 12 wells over three days post cell seeding. a-d, 
Line graphs for a 300 cells per well, b 500 cells per well, c 700 cells per well, d 1000 cells per well organoids to track 




Figure 3.13| PDX organoid volume and cell death tracking of 12 wells over three days post cell seeding. a-d, 
Line graphs for a 300 cells per well, b 500 cells per well, c 700 cells per well, d 1000 cells per well organoids to track 















Figure 3.14 | LN 229 organoid drug testing with 6 different concentrations of Dasatinib and Negative Control. 
a-g, Line graphs track organoid volume and cell death for 12 organoids over 9 days post cell seeding. Drugs of 
concentrations a 10uM, b 1uM, c 100nM, d 10nM, e 1nM f 100pM g Negative control (only dye in media solution) 

















Figure 3.15| PDX organoid drug testing with 6 different concentrations of Dasatinib and Negative Control. a-
g, Line graphs track organoid volume and cell death for 12 organoids over 9 days post cell seeding. Drugs of 
concentrations a 10uM, b 1uM, c 100nM, d 10nM, e 1nM f 100pM g Negative control (no drugs in media and dye 
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Chapter 4: Robust label-free microRNA detection using one 
million ISFET array 
 
In this chapter, we explore label-free technique for molecular sensing of microRNA with potential 
applications in personalized medicine. A 1024 X 1024 array of Ion Sensitive Field Effect 
Transistor (ISFET) based molecular sensors is reported for detection of nucleic acid molecules. 
Current microarray platforms use fluorescence labeling and thus require lab-scale setting. These 
optical DNA microarray chips could directly evolve into an electrical microarray, which has the 
potential to be less expensive, label-free, and could allow rapid detection of biomolecules with 
minimal utilization of resources. Using PNA probe functionalized on these ISFET array, we 
detected miRNA Let-7b by measuring changes in drain current after hybridization of target 
molecules with concentration as low as 1 nM. We demonstrate that mismatched or non-
complementary target molecules resulted in statistically smaller changes. The large sensing area 
on our chip allows high throughput experiments with various conditions tested on the same chip. 
Most importantly, the high-density sensor array showed unprecedented reliability and robustness 
with P values < 0.0001 for all experiments. Practical implementation of this platform could have 
a wide range of applications in high-throughput nucleic acid genotyping, detection of amplified 
pathogenic nucleic acid, and detection of cell-free DNA, and electrical readouts in current 
microarray technology. The work presented in this chapter was published in 20181. 
 
4.1 Introduction  
Electrical detection of biomolecules in a multiplexed manner is of great interest as it enables high-
throughput screening and assays. The detection and sequencing of DNA and RNA molecules is 
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useful for diagnostics, biological informatics, environmental monitoring and personalized 
precision medicine 2–4. Microarray revolutionized the nucleic acid detection market using top-
down semiconductor fabrication technology allowing thousands of target molecules to be 
interrogated simultaneously5. However, microarrays require fluorescent labeling and laboratory 
scale settings such as fluorimeters or laser scanners to read out and transduce optical signals 6. 
Lab-on-a-chip-based electrical detection of nucleic acids can overcome the aforementioned 
limitations enabling fast and affordable detection of specific sequences 7–9. A field effect transistor 
(FET) is a strong candidate as a miniaturized biomolecular sensor that can provide highly sensitive 
and specific detection of nucleic acids. Also, FET based biosensor technology does not need 
fluorescence labeling and optical components as it directly reads and transfers electrical signals to 
computer and personal electronics. Compatibility with CMOS fabrication process allows easy 
miniaturization and integration of a high-density array on a single chip. Therefore, FET based 
microarray can eliminate many limitations of current technologies. Many examples of arrayed 
electrical biosensors have been reported using planar silicon FETs, silicon nanowire, carbon 
nanotube and 2 dimensional materials such as graphene and MoS2 
6,7,10–12. However, none of these 
approaches has yet shown practically useful number of devices in an array to allow statistically 
robust detection. Moreover, reproducibility and reliability have been major issues for the 
abovementioned arrays, as 1-D and 2-D materials suffer from heterogeneity over the sensing area 
and poor reproducibility between product batches. This makes planar Si-based FET an ideal 
platform for practical development and commercialization of an electrical microarray sensing 
technology. We have recently reported massively parallel ion-sensitive field-effect transistor 
(ISFET) array using planar silicon transistors 13. Our chips are fabricated by  commercially 
available foundry and thus offer consistent manufacturing and reliability 14. Using this array we 
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have already shown pH sensing and pH based detection of foodborne bacterial pathogens13,15. 
Using this platform, we now present over million ISFETs as an electrical DNA chip array on a 7 
x 7 mm2 area with unprecedented reliability and robustness. Since a large number of transistors 
can be assigned to a single reaction in our devices, the variability or uncertainty in measurements 
is significantly reduced (P values < < 0.0001). Moreover, the large sensing area allows high 
throughput experiments and allows high numbers of repeating measurements at once thereby 
eliminating false-positives from non-specific binding of target molecules or from unwanted drift 
in field-effect transistors.  
 
The optical image and the schematic of the measurement system is shown in Figure 4.1. The 
structure and fabrication process of the array chip were reported earlier 13. To investigate the 
electrical properties of our FET devices, the output and transfer characteristics were measured 
prior to the functionalization of the PNA probe. As shown in Figure 1C, the typical Ids versus Vgs 
curves were obtained and showed only a small variation over the massive array. The standard 
deviation of Ids across all 1024 × 1024 pixels at Vfg = 1.7 was as low as 1.4626 µA which is less 
than 13 % of the mean. The various RNA detection experiments in this work were performed at a 
similar biasing voltage. The HfO2 gate dielectric sensing area was functionalized with PNA probe 
using (3-Aminopropyl)triethoxysilane (ATPES) and glutaraldehyde (Figure 4.2). For PNA-RNA 
hybridization detection test, microRNA (miRNA) Let-7b was used as a target molecule, which is 
a biomarker associated with human breast, lung, prostate, and other cancers 16. The basic approach 
for the nucleic acid molecule detection on a sensing pixel is demonstrated in Figure 4.1D. The 
source-drain current was measured before and after the hybridization, and ΔIds was calculated. For 
the specificity and negative control tests, miRNA-21 was used as the non-complementary RNA 
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17,18. To take advantage of the large sensing area of the array, different test conditions such as 
different concentration and other nucleic acids were measured on the same chip. Sequences of 
nucleic acids used in the experiments are presented in Table 4.1.  
 
4.2 Methods  
Chip fabrication: 
The FET array was fabricated at Taiwan Semiconductor Manufacturing Company (TSMC) with a 
process that was reported earlier 13 In short, standard metal-oxide-semiconductor (MOS) devices 
was fabricated in a silicon-on-insulator (SOI) wafer followed by bonding with carrier wafer. The 
sensing area was opened by lithography and dry-etch step and a hafnium oxide HfO2 layer was 
deposited to create sensing membrane of FET sensor. The high-K material, HfO2 acted as a top-
gate dielectric with the buffer solution. A cross-sectional schematic of one pixel is presented in 
Figure 4.1D. The decoder is integrated in the devices, which enables the read-out the current of 
1024 X 1024 of pixels in series. The integrated chip then connected to the PCB with wire-bonds.  
 
Testing setup: 
The integrated chip with PCB was connected with a PXI logic IC tester (OpenATE, Hsinchu, 
Taiwan). The IC tester controlled the decoder to select pixels and set bias conditions. The drain 
current of each pixel was then amplified and recorded. The measurement process is coordinated 
with custom-built software and recorded in CSV format in a personal computer. 
 
Probe functionalization: 
The chip was cleaned with O2 plasma for 3 min. Then the chip was reacted with 2% APTES in a 
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beaker for 2 hours. After rinsing with ethanol and DI water, the chip was soaked into 2.5% 
glutaraldehyde for 1 hour. A square PDMS well was placed on the chip to localize the probe. 10 
µM of the PNA probe was added into the PDMS well and kept for overnight at room temperature.  
 
Electrical measurement of hybridization events on a chip: 
The chip was rinsed with SSC buffer solution to remove non-specifically absorbed probes. Then 
the chip was measured with DI-water at Vfg = 1.7~2.0V. The hybridization was conducted by 
adding complementary or mismatched RNA with concentrations that are indicated in the legends 
in Figures 4.4 and 4.5 and incubated for 30-60 minutes in the PDMS reservoir on the FET chip. 
Then, the chip was rinsed gently with DI water. I-V curves and resistance were measured by the 
experimental settings mentioned above in DI water. Ag/AgCl electrode was used as a gate 
electrode, which swept fluid voltage (Vfg) to the buffer solution directly.  
 
 
4.3 Results and Discussion 
The array of  silicon FETs was fabricated at Taiwan Semiconductor Manufacturing Company 
(TSMC) foundries following the previously reported methods 13. Briefly, SOI (Silicon on 
Insulator) was used as an active channel and each of the FET was isolated by SiO2. Top gate 
voltage was applied from the fluid above the sensor using a Ag/AgCl electrode (fluid gate). Back-
gate to the channel was also available and biased at a fixed voltage. Notably, in our FET arrays, a 
high-k dielectric material, hafnium oxide, was deposited by ALD over the entire chip area, creating 
the FET sensing membrane. This high-k dielectric reduces ion transport across the dielectric as 
compared to the traditional top gate dielectrics such as silicon dioxide 19. Dimension of each of the 
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pixel was 7 × 7 µm2 and the whole sensing area was 7 × 7 mm2, which is comparable in size with 
a conventional high-density microarray chips. The schematic of the sensor structure is presented 
in Figure 4.1(A). The top-view of the architecture is shown in Figure 1 and includes sensing area, 
row/column decoders, and wire-bonds to PCB. 
 
The FET chip was connected to a PXI logic IC tester. The tester established the coordination with 
a Spectrum transient recorder (Spectrum, Grosshansdorf, DE). The decoding circuits selected each 
FET and controlled the biasing voltage. The measurement of the entire 1024 × 1024 array of FETs 
was performed in approximately 90 seconds. The measurement data was transferred via a 
customized MTS3 software in a comma separated values (csv) file format for later analyses. The 
scheme of the setup is in Figure 4.1B. 
 
To create a solution reservoir of the buffer solution as a liquid gate, a 400 μL PDMS well was 
bonded on the chip leaving the sensing area open. The basic characterization of the BioFETs was 
performed before the nucleic acid detection tests. Figure 1 shows the transfer characteristics of 
FET array as a function of the drain current (Ids) vs. fluid-gate voltage (Vfg). Vfg was swept from 
1.5 to 1.9 V with a constant drain voltage of 2 V to obtain transfer curves. Figure 1C is an overlaid 
3D graph of the multiple drain currents of each sensor with different Vfg biasing values. There is 
a ‘dummy diagonal’ sensors reference line that is used for validation of the chip fabrication and 
performance. Figure 4.1 presents the transfer curve of standard transistor characteristics for the 
entire array (excluding dummy pixels) and shows very low standard deviation across all the 




FET based biosensors can be vulnerable to effect of temperature changes, hysteresis, and drift 17. 
When using DI water as a fluid gate, a drift, can be observed versus time without applying any 
voltage or adding charged biomolecules. In this work, the drift effect and its compensation have 
been carefully studied and used to optimize our measurement/sensing protocol. Even though some 
spatial variations were observed across the chips, the performance of these foundry-fabricated 
sensors is highly robust.   
 
To study the drift in sensors over time, we simulated a negative control (no nucleic acid) reaction 
by adding only DI water on the sensor array. Then, Ids was measured at a fluid gate voltage Vfg of 
1.75V at time 0 and after 1 hour of exposure of the sensors to the DI water. Changes in this drain 
current (t1hour -t0) as a color map in Figure 4.2(A) shows the spatial variation over time in the 
transistor current due to drift. To compensate or correct for this drift, we varied the biasing voltage 
at the 1 hour measurement until the change in drain current became 0 for all the transistors in the 
array. The results of drift compensation at different biasing voltages is shown in Figures 2B-D. At 
1.785 V (Figure 4.2D), the spatial variation and pseudo-field effect was clearly compensated. The 
summary of the drift compensation is shown in Figure 2E with mean and standard deviation graph 
of ΔIds.This drift compensation was possible for our array since the drifts of the individual FETs 
in the array our tied together. This also implies that one region of the array can be kept as a negative 
control (no nucleic acid) and real-time drift correction for this region would compensate the drift 
effects for the entire array. After the compensation, measurement conditions are very stable and 
conducive for detection of biomolecular binding events over the entire array. If uncorrected, the 
drift can result in false-positive signals affecting the sensitivity of the assay. Thus, it is important 
to utilize the reference sensing area to compensate the drift values, and this compensation is easily 
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possible with our large sensor array. This unique real-time drift correction feature of our platform 
allows drift compensation at any data collection time point making our assay immune to drift 
effects. 
After the basic characterizations of the chip, the actual nucleic acid detection experiments were 
performed. In order to take advantage of the sensor array, different concentrations of target 
molecules were tested on the same chip at the same time. This was possible not only because the 
chip has a large sensor array but also because the variation in performance of each FET was very 
small. To conduct multiple experiments on one chip, a PDMS well with 9 holes which served as 
separate reaction chambers was used for the nucleic acids detection experiments. A picture of the 
experimental setting including the PDMS well is shown in Figure 4.7. PNA was chosen as the 
probe molecule since PNA does not contain a charged phosphate backbone making the binding 
between PNA and other nucleic acids stronger than that between DNA/DNA or DNA/RNA strands 
3,6. Moreover, uncharged PNA molecules do not result in electrical modulation of the 
semiconductor channel unless the target hybridization occurs, thus eliminating any background 
electrical noise issues from the probe 3,20,21. To functionalize the surface of the chip with PNA 
probes, the hafnium oxide surface was hydroxylated by O2 plasma. The surface was then treated 
with (3-Aminopropyl)triethoxysilane solution (APTES – 2% ethanol) for silanization and then 
reacted with glutaraldehyde (2.5%) to generate a self-assembled monolayer with terminal aldehyde 
group. This terminal aldehyde group is then covalently bonded with amine group at the 5’ side of 
PNA probe (Figure 4.3) 17,22. The sensor array at this stage is ready for target hybridization. 
 
The sensitivity of the FET array biosensor was investigated by conducting hybridization of various 
concentrations of complementary RNA strands on the PNA-functionalized FET devices, are 
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shown in Figure 4.4(A). DI water was used as the reference negative control. Figure 4B shows an 
electrical 3D plot of the drain current matrix presenting the multiple drain currents versus different 
concentrations of target strands along with the negative control. As the chip has large numbers of 
sensing array, variance between each was also FET was assessed. Figure 4C shows the summary 
of shifts of Ids at the corresponding concentrations, which shows that ΔIds is dependent on the 
concentration of the complementary RNA. A detection limit of 1 nM was achieved based on the 
signal that exceeds the background level by 37.5 % difference (p value<<0.0001). This 
concentration level is comparable to what is used in the current microarray technology 23. 
However, as shown in the Figure 4C, the P values of results are less than 0.0001 indicating that 
this array sensor is extremely reliable and is robust against noise artifacts that can arise due to 
various processing steps. A repeat experiment for Figure 4.4 is shown in Figure 4.8.  
 
The Debye length should be considered when detecting electrical charge in ionic solution. The 
Debye length represents the distance over which the charge is shield in an ionic solution where 
counter-ions can shield the original charge 3. In the 1X SSC solution, which is generally used as a 
DNA buffer solution, the Debye length is <1 nm. Therefore, DI water was used for electrical 
detection after the hybridization process. To verify the specificity of our biosensor assay, 
complementary Let7b miRNA and non-complementary miRNA-21 were introduced for 
hybridization on the PNA-functionalized FET array. Figure 4.5 shows transfer characteristics of 
the PNA-immobilized FET biosensors incubated with 1M of Let-7b and miRNA-21. The results 
Figureshow the shifts of Ids of the FETs for complementary miRNA was much larger and 
distinguishable (p<<0.0001) than that for non-complementary RNA. The ΔIds was 1.8 μA, 1 μA 
and 0.2 μA for complementary RNA, non-complementary RNA and no target negative control, 
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respectively. The ΔIds of non-complementary RNA might be caused by a small amount of non-
specific adsorption but since our platform has a large number of FETs per reaction even while 
testing multiple conditions on the same chip (~15000), the p-value for different conditions is 
extremely low. The data confirms that the biosensors can distinguish the complementary DNA 
from mismatched RNAs and can be used for miRNA detection.  
Finally, to further assess the statistical robustness of our assay, we evaluated the effect of large 
number of transistors on the p-value in our experiments. Using the limit of detection experiments 
from Figure 4.4, we calculated the p-value between different test conditions (concentrations) as a 
function of number of transistors used in the reaction. As can be seen from Figure 6, in our assay 
the difference between different concentrations and the negative control is highly significant. The 
plots in Figures 4.6B-E show that for experiments with low number of transistors, the p-value is 
higher and very variable. However, as the transistor count per reaction increases, especially above 
a few hundred transistor, the p-value becomes very low for all test conditions suggesting that the 
system becomes very reliable and robust against noise artifacts. The large number of sensors pixels 
within one fluid well is important as this truly takes advantage of the VLSI silicon fabrication to 
reduce the p values and increases the reliability and robustness of the sensing. If a small number 
of devices is used then large p value, reflective of the variability in the molecular binding events 
can result in the lack of ability to discriminate across the concentrations of the target molecule.  
 
The original microarray was inspired by fabrication process of transistor array in electronics to 
fabricate massive number of micro-sized spots on a chip. The proposed biosensor finally 
demonstrates a prototype of an electrical microarray with more than one million FET sensors in a 
single chip. These array sensors would not need fluorescence labeling or optical components and 
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would reduce false-positive signals due to the unprecedented large number of sensors in one chip 
and within one fluid reaction well. The chip is commercialization-ready since it is foundry based, 
and shows high reliability, robustness and reproducibility. Further development and 
implementation of this technology would allow more affordable and accurate diagnosis of myriad 




4.4 Chapter Summary 
Label-free detection of miRNA with high resolution was achieved by using a massively parallel 
and multiplexed FET array. The PNA modified FET biosensor exhibits limit of detection of 1 nM 
and can also discriminate between complementary miRNA from mismatched RNAs with high 
specificity. The work provides a significantly improved platform for biomolecular detection by 
using foundry based Silicon on Insulator FET technology. It provides high fidelity and 
reproducibility which not been achieved with 1- or 2-D materials such as nanowire, carbon 
nanotube and graphene because of inherent heterogeneity of these materials. Our results 
demonstrate the practical utility of the biosensor technology and expand their use as an electrical 
microarray technology. This opens opportunities for the development of more reliable and efficient 
diagnostic tools, including design and development of miniaturized and point-of-care biosensors 
for high-throughput screening to detect potentially life-threatening human diseases, drug 






4.5 Figures and Table 
 
 
Figure 4.1 | A million FET sensor array chip image and the measurement set up. (A) Top-view of the 
sensor array. The black arrow indicates the 1024 × 1024 array in 7 × 7 mm2 sensing area. (B) The testing 
setup describing the PCB, TIA (transimpedance amplifier) and wire-bonds to PCB. (C) 3D map (left) and 
overall population (right) of whole array of drain-source current as a function of Vfg. The error bars are 
standard deviation. (D) Schematic cross-section of one sensor pixel. The relevant structures and 







Figure 4.2| Real-time drift compensation of the 1024 × 1024 biosensor array. (A) After adding DI water 
as a liquid gate on the sensing area ΔIds was measured at Vfg = 1.75 V before and after 1 hour The array 
showed non zero ΔIds with a spatial variation owing to the drift effect. (B) ΔIds was measured again with a 
new biasing voltage of  Vfg = 1.77 V for the 1 hour measurement. The spatial map shows reduced ΔIds 
values. (C) At Vfg = 1.78 V, the map showed a a very small variation and drift was almost compensated. 
(D) Drift was completely compensated with very little spatial variation at Vfg = 1.785 V. The scale 
represents ΔIds  in µA. (E) Graph shows the real-time drift compensation as reducing ΔIds values with 
different biasing voltages. Mean of ΔIds ~ 0 for Vfg = 1.785 marks the completion of real-time drift 






Figure 4.3| Schematic of the surface functionalization of the HfO2 for miRNA sensing. (A) The 
hafnium oxide surface was hydroxylated by O2 plasma. (B) The surface was then silanization by APTES. 
(C) Covalent bonding between the Amide group and glutaraldehyde. (D) PNA functionalization with the 








Figure 4.4| miRNA-let7 detection on the FET array. (A) Heat map of drain current with different 
concentrations of target RNA in the array. The numbers in white represent concentrations of the target in 
nM. NC is negative control where no nucleic acid target was present. (B) 3D plot of (A). The scale of the 
color code in (A) and (B) represents Ids in µA. There are some spots resulting in noise but given the large 
number of pixels, the noise can easily be removed and eliminated. (C) Change of Ids curve as a function of 
the target Let7b concentration. The NC shifts the Ids significantly less. Statistical values (means ± standard 







Figure 4.5 | Specificity test with perfect matched (Let-7b) and non-complementary miRNA (miR-21)  
(A) Heat map of drain current of the array with different target and non-complementary RNA. The white 
numbers represent types of the target, 21 is miR-21. NC is negative control; no target was treated. (B) 3D 
plot of (A) The scale of the color code in (A) and (B) represents Ids in µA. Summary of shift of Ids curves. 
The miR-21 shifts the Ids significantly less. Statistical values (means ± standard deviation) were based on 









Figure 4.6| The effect of large number of transistors on the p-value. The p-values between different test 
conditions (concentrations) were calculated using student’s t-test as a function of number of transistors used 
in the reaction. (A) The schematic shows the increasing number of the pixels randomly selected for the p-
value calculation. (B-E) P-value graphs comparing two different concentrations as indicated in the top of 
graphs. For experiments with low number of transistors (3 to 10), the p-value is higher and very variable. 
As the transistor count per reaction increases, the p-value becomes very low for all test conditions 
suggesting that the system becomes very reliable and robust against noise artifacts. The error bars are 








Figure 4.7| (A) Picture of the testing setup describing the PCB and 9-hole PDMS well which was used for 





Figure 4.8| Another set of miRNA-let7 detection on BioFET array. Heat map (left) of drain current with 
different concentrations of target RNA in the array. (B) Summary of shift of Ids curve as a function of the 
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Chapter 5: Hands-free smartphone-based diagnostics for 
simultaneous detection of Zika, Chikungunya, and Dengue at 
point-of-care 
 
Infectious diseases remain the world’s top contributors to death and disability, and, with recent 
outbreaks of Zika virus infections there has been an urgency for simple, sensitive and easily 
translatable point-of-care tests. Here we demonstrate a novel point-of-care platform to diagnose 
infectious diseases from whole blood samples. A microfluidic platform performs minimal sample 
processing in a user-friendly diagnostics card followed by real-time reverse-transcription loop-
mediated isothermal amplification (RT-LAMP) on the same card with pre-dried primers specific 
to viral targets. Our point-of-care platform uses a commercial smartphone to acquire real-time 
images of the amplification reaction and displays a visual read-out of the assay. We apply this 
system to detect closely related Zika, Dengue (types 1 and 3) and Chikungunya virus infections 
from whole blood on the same pre-printed chip with high specificity and clinically relevant 
sensitivity. Limit of detection of 1.56e5 PFU/mL of Zika virus from whole blood was achieved 
through our platform. With the ability to quantitate the target nucleic acid, this platform can also 
perform point-of-care patient surveillance for pathogen load or select biomarkers in whole blood. 
The work presented in this chapter was published in 20171. 
 
 
5.1 Introduction  
 
A member of the family Flaviviridae, genus Flavivirus, Zika virus appeared in the international 
spotlight in late 2015 as evidence emerged of a possible link between an epidemic affecting Brazil 
and increased rates of microcephaly in newborns.2  Like other febrile virus infections such as 
Dengue and Chikungunya, Zika virus is transmitted by the bite of infected Aedes aegypti and Aedes 
albopictus mosquitos.3 Human-to-human spread is also well documented, including in utero 
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transmission from mother to fetus, sexual transmission, and in one unusual case, non-sexual spread 
through close contact with an individual of high viremia, likely sweat or tears.4 While most Zika 
virus infections are asymptomatic, those who manifest disease typically exhibit non-specific 
symptoms including to varying degrees: rash, fever, arthralgia, conjunctivitis, myalgia, headache, 
retro-orbital pain, edema, and vomiting,5,6 many of which overlap significantly with acute Dengue 
and Chikungunya virus infections. Moreover, Zika virus infection has been reported to cause 
Guillain-Barré syndrome, a neurological complication involving progressive paralysis capable of 
resulting in respiratory failure and death.4,5 
 
The non-specific presentation of Zika virus symptoms and shared vectors with other febrile 
diseases such as Dengue and Chikungunya present a significant diagnostic challenge: no 
combination of symptoms is adequately unique to make a clinical diagnosis of Zika virus. The 
problem is aggravated in some resource-limited regions where all the three virus infections are 
endemic resulting in the need for specific diagnosis for informed clinical intervention, better 
patient management, and epidemiological surveillance.7,8 This creates a need for low-cost and 
portable platforms that can provide fast, accurate, and multiplexed diagnosis of all such diseases 
at the point-of-care. The current gold standard in Zika virus detection involves nucleic acid 
detection (RT-PCR) and antibody serology with an immunoassay.4 A major challenge, however, 
is cross-reactivity of antibodies in individuals with prior Dengue infection, rendering serology an 
imperfect approach that can be difficult to interpret in such scenarios.4 RT-PCR, meanwhile, 
remains an expensive, highly-technical, and time-consuming method making it incompatible in 




Loop-mediated isothermal amplification (LAMP), emerged within the last two decades as an 
alternative to PCR for nucleic acid amplification.9 This method has been leveraged for higher 
specificity of its 4-6 primer systems, single-temperature incubation, and increased resistance of 
the Bst polymerase to inhibitors that prevent PCR. LAMP and RT-LAMP have been employed in 
the literature for a variety of nucleic acid detection applications including point-of-care 
platforms.10–14 and, in just a few recent reports, Zika virus detection.15–18 Few, however, have 
leveraged the robustness of the LAMP polymerase for detection of pathogens directly in 
unprocessed whole blood.10,19–21 The detection of Zika virus is confounded by the short window 
of detection of the virus in serum, urine, and saliva 22–24. However, two independent reports have 
suggested detectable amounts of Zika viremia in whole blood for up to 2 months,25 and 81 days26 
after the onset of symptoms and attributed this prolonged Zika viremia presence to the erythrocyte 
component of whole blood. Several other studies on West Nile and Dengue viruses have reported 
similar findings showing a large proportion of viruses bound to red blood cells leading to 10-fold 
higher concentrations and much longer persistence of viruses in whole blood compared to plasma 
27–31. These findings suggest whole blood is likely the ideal body fluid for diagnosis as well as 
long-term viral load monitoring in Zika infection. To date there have been no point-of-care assays 
reported which include this erythrocyte-associated component with minimal sample 
processing15,32. Additionally, none of the previously published literature on LAMP-based Zika 
diagnostics have answered the critical concern of multiplexing multiple closely related viruses on 
a single platform.  
 
Herein, we report an integrated, lab-on-a-chip method for detection of Zika virus in spiked whole 
human blood employing complete hands-free sample processing, a unique RT-LAMP assay, and 
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smartphone imaging. Our assay is quantitative and can detect down to 10 PFU/reaction which 
corresponds to 1.56e5 PFU/mL of Zika virus in infected blood in under 35 minutes with minimal 
sample processing. To further extend the clinical significance of our work, we multiplex the 
detection of Zika virus with RNA from other closely related viruses- Dengue virus types 1 and 3, 
and Chikungunya virus on a single microchip. We demonstrate the only platform to date that can 
multiplex detection of viral and other nucleic acid targets on a portable point-of-care setup starting 
from whole blood samples. 
 
5.2 Methods  
 
RT-LAMP reaction composition: 
All RT-LAMP assays comprised of the following components: 1x final concentration of the 
isothermal amplification buffer (New England Biolabs), 1.4mmol/L each of deoxy-ribonucleoside 
triphosphates (dNTPs), 10mmol/L of MgSO4 (New England Biolabs), and 0.4 mol/L of Betaine 
(Sigma-Aldrich). These components were prepared in bulk and stored at –20 °C between 
experiments. In addition to the buffer components, 3 μL of primer mix consisting of 0.2 μM of F3 
and B3, 1.6 μM FIP and BIP, and 0.8 μM of LoopF and LoopB, 0.64 U/μL Bst 2.0 WarmStart 
DNA Polymerase (New England Biolabs), 0.08 U/μL AMV reverse transcriptase (New England 
Biolabs), and 1× EvaGreen (Biotium), a double-stranded DNA (dsDNA) intercalating dye, was 
included in the reaction. 8 μL template of the appropriate concentration and 0.05 μL of DEPC-
treated water (Invitrogen) was added to make the final reaction volume 25 μL.  
 
The RT-PCR reaction was carried with iTaq™ Universal One-Step RT-qPCR Kit (Bio-Rad 
Technologies). Briefly, a 20 µL final reaction mix contained 10 µL of 2x iTaq universal probes 
reaction mix, 0.5 µL of iScript advanced reverse transcriptase, 2 µL of 0.4 µM forward primer, 2 
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µL of 0.4 µM reverse primer,2.8 µL of 0.2 µM probe, and 2.7 µL of template RNA.  
 
The templates for the Zika virus RT-LAMP characterization consisted of either purified RNA in 
water, or whole virus particles spiked in whole blood. Ten-fold serial dilutions of the templates in 
appropriate buffer were amplified to determine the working range of our developed assays. The 
RT-PCR reactions were performed with purified RNA in water. For the multiplexing tests, the 
templates for Dengue-1, Dengue-3, and Chikungunya virus consisted of the corresponding viral 
RNA spiked in whole blood and the Zika virus template consisted of whole Zika virus spiked in 
whole blood. The off-chip co-infection test included an amalgam of purified viral RNA in water 
such that the final concentration of each target was 1000 PFU/reaction. All the off-chip and on-
chip RT-LAMP and RT-PCR reactions consisted of non-template negative controls that were 
included in all the datasets. In the on-chip experiments, these non-template negative controls on-
chip were prepared off-chip and injected into the appropriate lanes manually using a syringe. 
Additionally, the on-chip tests also included no primer negative controls to check for any cross-
talk between adjacent wells.   
 
Reaction platforms: 
All the off-chip LAMP tests were carried out in 0.2 mL PCR reaction tubes in an Eppendorf 
Mastercycler® realplex Real-Time PCR System. The tubes were incubated at 65 °C for 50 minutes 
in the thermocycler, and fluorescence data was recorded every 1 minute. The off-chip PCR tests 
were conducted on the same thermocycler but with the following recipe: RT incubation at 50 °C 
for 10 minutes, 3 minutes of DNA denaturation at 95 °C, and 45 cycles of thermocycling from 95 
°C (15 seconds) to 60 °C (60 seconds). Fluorescence data was recorded after each cycle of the 
reaction. All the on-chip experiments were carried out on a silicon biochip using our integrated 
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point-of-care imaging and heating setup as described below. 
 
Sample processing module: 
The microfluidic sample processing module was adapted from the work of Watkins et. al.33 
Polydimethylsiloxane (PDMS) was synthesized and poured over a SU-8 master mold fabricated 
using standard cleanroom photolithography techniques. The PDMS was then degassed in a vacuum 
desiccator and incubated in a 60 C oven for 2-3 hours to cure. Cured PDMS block of thickness 
approximately 5 mm was then cut out from the mold and cleaned with Isopropyl Alcohol (IPA) 
followed by drying with dry nitrogen to remove any impurities from the microfluidic channels. 
Three inlet holes and one outlet hole were drilled into the PDMS using a 0.5 mm needle, for tubing 
connections. Afterwards, the surfaces of the processed PDMS and a clean glass slide were 
activated via oxygen plasma activation in a DIENER PICO plasma system. Immediately following 
this, PDMS and glass slide were covalently bonded to each other over a hot plate at 120°C to form 
the complete sample processing module. 
 
The sample processing module consisted of three inlet ports for three different solutions- whole 
Zika virus or other viral RNA spiked whole blood, RT-LAMP reagents and lysis buffer. The flow 
rates were controlled using syringe pumps, and were fixed at 1 µL/min, 3 µL/min, and 10.62 
µL/min for virus/RNA in whole blood, lysis buffer, and RT-LAMP reagents respectively. This 






Amplification chip fabrication: 
The oxidized silicon chip was roughly the size of a quarter (29 mm × 29mm) and has 6 
interconnected channels at the center and 2 separate, independent channels along the periphery. 
Flow channel dimensions were 10 mm in length, 500 µm in width and 200 µm in depth, 
representing a volume of 1µL per channel. The inlet of the chip was a 2 mm diameter circle. A 4-
inch <100> silicon wafer (University Wafer, South Boston, MA) with one side polished was 
thoroughly cleaned and used as the substrate in the photolithography process. Positive photoresist 
SPR 220 (MicroChem, Newton, MA) was spin-coated on the polished side of the wafer to form a 
4.5 µm covering layer, followed by the soft-bake at 60°C for 2 min and 110°C for 1 min. The 
photoresist was then exposed with an i-line (365 nm) mask aligner (EVG 620) with an expose dose 
of 180 J/cm2. The exposed regions with the outline of the microfluidic pattern were subsequently 
removed by immersing the wafer in AZ developer diluted 1:4 with deionized (DI) water for 4 min. 
The photoresist in the unexposed regions was solidified though a hard-bake at 110 °C for 1 min. 
For the anisotropic etching of the silicon substrate, a Bosch process RIE with alternating steps of 
SF6/O2 etching and C4F8 passivation was used to create a 200 µm deep trench. After the Bosch 
process, the remaining photoresist was stripped with acetone and O2 plasma cleaning, leaving the 
bare silicon exposed. Finally, the wafer was thermally oxidized in a furnace (1150°C) for 2 hours 
to grow 200 nm SiO2 and subsequently scribed into individual chips.  
 
 
Cradle fabrication and smartphone based fluorescence imaging: 
The optical imaging system used to excite and detect fluorescent emission from the LAMP assay 
is depicted in Figure 5.1. The system is composed of a smartphone (Nexus 6; Motorola, IL, USA) 
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and a portable 3D-printed cradle that supports the optical and electrical components and interfaces 
with the rear-facing camera (13 megapixels, pixel size of 1.4 µm) of the smartphone. Not only 
does the cradle align the camera with the components, but it serves as a dark chamber for pure 
fluorescence detection by blocking out external light. The smartphone paired with the cradle takes 
photos of the chip at 1-minute intervals to and communicates with a cloud-connected external 
computing system to process image data.  
 
A schematic of the system is shown in Figure 5.13b. The top part of the cradle holds the 
smartphone and allows the rear-facing camera to align with an opening that supports a macro lens 
(12.5X) and a long pass filter (525 nm). The macro lens is placed in front of the camera to enable 
close-up photography of the chip, which reduces the distance between the camera and the chip to 
50 mm, while keeping the 29 X 29 mm chip within the field of view. The long pass filter allows 
only light generated by the assay fluorophores to be transmitted to the camera. A light-emitting 
diode (LED) module composed of eight SMD type blue LEDs (λpeak = 485 nm, Vforward = 3.1 V) 
and four short pass filters (490 nm) that cover each pair of LEDs is installed in the cradle to excite 
fluorescence of the EvaGreen intercalating dye. The LEDs are mounted on a printed circuit board 
(PCB) and arranged with square symmetry to provide uniform illumination over the microfluidic 
chip area. The light source module is powered and operated by an Arduino Gemma, which is an 
open-source electronics platform composed of a programmable circuit board and control software. 
The Arduino microcontroller board is powered by a lithium-ion battery (3.7 V) and provides 3.3V 
output by a built-in voltage regulator that powers all eight LEDs consistently. The preprogrammed 
Arduino board regulates the duty cycle and operation frequency of the LED On-Off switching 
during a measurement. For experiments with viral RNA in water, the LED “on” time was 6.1 
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seconds, and the “off” time was 53.9 seconds, and for experiments of RNA/whole virus particles 
in whole blood, the LED “on” time was set to 10 seconds, and the “off”time was set to be 50 
seconds. The card that contains the amplification chip is inserted into the cradle such that it is in 
contact with the positive temperature coefficient (PTC) heater that allows the chip temperature to 
stabilize near 65 C without an external temperature controller. The PTC heater is made from a 
ceramic material that functions as a self-regulating heating element, such that when the 
temperature of the PTC heating element increases, the electrical resistance increases nonlinearly 
resulting in decreased heat output to set the temperature at a predesigned limit. The PTC heater 
does not require an over-temperature protector, while providing uniform heating, low-voltage 
operation, and light weight. The PTC heater (12V-80 ˚C; Uxcell, Hong Kong, China) is powered 
by a battery set (10.5V) composed of two standard 9V batteries and two 1.5V AA batteries each 
to set the temperature of the microfluidic chip around 66 ~ 68 C for 60 minutes to perform one 
LAMP assay (Figure 5.14). The LEDs and the heater are turned on and off by two separate toggle 
switches. The transmitted fluorescent light through the macro lens and long pass filter is captured 
using the smartphone rear-facing camera in an 8-bit 3-channel JPG image format. The overall 
dimensions of the system are ~ 90 X 70 X 95 mm3.  
 
Amplification chip preparation, chip assembly, and chip sealing:  
All the microfluidic chips for on-chip RT-LAMP experiments were cleaned in the following steps: 
First, the chip was cleaned in a Piranha solution containing 1:3 of 30% hydrogen peroxide and 
sulfuric acid for 10 minutes followed by extensive rinsing with deionized water to remove any 
acidic residues. Then, the chip was dried using nitrogen gas and immersed in Sigmacote (Sigma-
Aldrich) in a sterile petri dish for approximately 5 minutes to make the surface of the chip and its 
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channels hydrophobic. This was done to prevent any non-specific adsorption of biomolecules on 
the chip surface during the RT-LAMP reactions.34 The chip was then rinsed with isopropanol 
before being blow-dried with nitrogen gas. Chips were placed in sterile glass petri dishes until use.  
 
Primers were printed on the positive and non-template negative reaction channels followed by a 
short incubation period at room temperature to dry the primers. Briefly, 1x concentration of the 
primer was diluted in 1:3 ratios in DEPC treated water and two drops of 0.24 µL of primers were 
pipetted and left to dry at room temperature for 30 minutes. Following drying, double sided 
adhesive membranes (ARSeal 90880, Adhesive Research), each with 11 laser-cut holes attached 
to three small PDMS blocks with holes drilled by a 0.5 mm needle was aligned and attached to the 
microfluidic silicon chips. PDMS blocks were aligned with three inlet ports on the chip- a central 
inlet port for sample injection, and two peripheral inlet ports for injection of non-template negative 
controls. The assembled chips were stored in a desiccator until use.  
 
For experiments with viral nucleic acids in water, the template and the RT-LAMP reagents were 
mixed off-chip, and then injected into the chip using a syringe pump. Once the sample was loaded 
into the chip, the outer layer of the double-sided adhesive which contained the PDMS blocks was 
peeled off, and the chip was sealed with a second double-sided adhesive layer to prevent 
evaporation during RT-LAMP incubation. The chip was placed on a credit card sized cartridge 
(85.6 mm×54.0 mm×0.8 mm), and the cartridge containing the amplification chip was inserted 
into our portable point-of-care setup for RT-LAMP reaction, and real-time monitoring. The 
cartridge fit snugly inside the cradle which ensured good contact with the heater throughout the 




For any experiments involving blood, the sample processing chip and the amplification chip were 
assembled together on the cartridge (Figure 5.1). A tube from the outlet of the pre-processing chip 
connected the sample injection port of the amplification chip ensuring rapid, reliable, and 
automated mixing and sample loading into the amplification chip. The amplification chip was 
visually observed for filling, and the connecting tube was manually disconnected once filling was 
complete.  The chip was sealed in the same procedure as described above. The cartridge containing 
both the sample preprocessing chip and the amplification chip was inserted into the cradle. The 
amplification chip rested atop the heater inside the cradle while pre-processing chip stuck out. 
Biosafety level-2 protocol was observed in all experiments with live viruses.  
 
Image and data analysis: 
Images recorded with IP Webcam in smartphones were saved in TIFF format from which 
fluorescence intensity was analyzed in an automated fashion using a MATLAB script. Grayscale 
images were first imported as an array of 8-bit unsigned integers (range 0-255), which represented 
each pixel in the image. Then, the average fluorescence intensity from only the channel portions 
of the chip were extracted using a polygonal virtual mask. Such time-lapsed fluorescence values 
for each channel were obtained from the images and a fluorescence vs time curve was plotted. The 
baseline (initial) fluorescence value was subtracted for each curve to account for the differences 
in starting fluorescence values per channel. The fluorescence measurements in the data were in 
arbitrary units (AU).    
 
All on-chip and off-chip RT-LAMP and RT-PCR data was analyzed and plotted using a MATLAB 
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script. For all the off-chip and on-chip experiments, the threshold time was taken as the time taken 
for an amplification curve to reach 20% of its maximum intensity. For on-chip reactions, the 
fluorescent intensity on-chip was extracted from each channel and was plotted against time to 
generate the raw fluorescence curves. Each raw amplification curve was fitted to a sigmoidal curve 
using a four-point parameter modeling (Figure 5.12). The following equation was used for the 
analysis:  
𝑓 = 𝑦0 +  
𝑎





Where f = fluorescence intensity, 𝑦0 = background fluorescence at time = 0 minutes, 𝑎 = difference 
between the initial and final fluorescent intensity, x = time point of analysis, 𝑥0 = inflection point 
of the curve, b = slope of the curve. The threshold time was obtained at the point where the 
fluorescent intensity = 𝑦0 + 0.2∗ 𝑎. The positive and negative wells were differentiated based on 
the R2 value of the sigmoidal fit and the parameters  𝑎  and  𝑥0. Negative wells had a combination 
of low R2 value, low 𝑎 value, or a very high threshold time (𝑥0>50 mins). 
 
Whole Zika Virus: Zika Virus, MR 766, NR-50065 was obtained through BEI Resources, NIAID, 
NIH, as part of the WRCEVA program. Zika Virus, PRVABC59, NR-50240 was obtained through 
BEI Resources, NIAID, NIH. The stock vial was aliquoted and stored at -80C. Appropriate stock 
volumes were used either for direct experimentation with the viruses or for RNA extraction. For 
experiments using whole viruses directly, the appropriate stock volume of the virus was diluted to 
the right concentrations either in whole blood. The whole venous blood samples were drawn from 
healthy, consenting, Zika virus -negative adult volunteers with a syringe, which were later 
transferred to 4 mL BD Vacutainer K2 EDTA collection tubes. The tubes were stored in a sample 




Viral nucleic acids: Zika virus RNA was purified from whole Zika virus particles using RNeasy 
Mini Kit (Qiagen). Genomic RNA from Dengue Virus Type 1, Hawaii, NR-4287, and genomic 
RNA from Dengue Virus Type 3 (DEN-3), Philippines/H87/1956, NR-2771 was obtained through 
BEI Resources, NIAID, NIH.  Quantitative Synthetic Chikungunya virus 
(CHIKV) RNA (ATCC® VR3246SD™) was purchased from American Type Culture Collection 
(ATCC). The purified RNA was aliquoted and stored at -80 C until used for experiments. The 
stock viral RNA was diluted in either DPEC water or whole blood depending on the experiments. 
 
Cell lysis buffer: Blood lysis buffer were prepared in accordance with the work of Curtis et. al,19,20 
and consisted of 2.5 mmol.L–1 KHCO3, 37.5 mmol.L–1 NH4Cl, and 0.025 mmol.L–1 EDTA. For 
all experiments involving lysed blood, a 1:4 ratio of blood to lysis buffer was used. A manual 
pipettor was used to gauge and mix blood with lysis buffer for all off-chip experiments on a 
benchtop thermocycler. For microfluidic on-chip RT-LAMP experiments with whole virus 
particles/viral RNA in blood, lysis buffer and blood were mixed using a microfluidic on-chip pre-
processing module which is explained in the section below. The flow rates for the blood and lysis 





5.3 Overview of approach 
 
Figure 5.1 shows the process flow for our on-chip multiplexed pathogen detection from a finger 
prick of whole blood sample. Our point-of-care diagnostics and monitoring platform can be 
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divided into three primary modules: A, B and C. Module A is a polydimethylsiloxane (PDMS) 
microfluidic sample processing chip where infected whole blood is first lysed and then mixed with 
amplification reagents. This chip has three inlets ports for infected blood, lysing buffer and RT-
LAMP amplification reagents respectively, and one outlet port for amplification-ready processed 
analyte. The robustness of RT-LAMP reaction to inhibitors allows for replacing the usual RNA 
purification steps required before amplification reactions with simple cell lysis and our on-chip 
sample processing module A translates the routine manual pipetting steps to a complete hands-off 
platform. Next, the processed sample from Module A is transferred to Module B, which is an 
oxidized silicon chip with six etched micro-channels (1cm X 500µm X 200µm), for isothermal 
amplification at 65C. RT-LAMP primers specific to different pathogens are pre-dried in different 
channels of the chip as a part of chip preparation. After the processed sample is transferred into 
these channels, the chip is sealed with a silicone based adhesive (ARseal™ 90880, Adhesives 
Research) to prevent sample evaporation during incubation. As shown in Figure 5.1, the modules 
A and B are incorporated in a “diagnostics card” which is similar to a credit card in appearance 
and this card can be customized according to the pathogens to be detected or quantified in the 
patient blood by pre-printing the specific primers. Module C is our point-of-care setup comprising 
of a commercial smartphone, an in-built heater and the essential optics/optical accessories for real-
time fluorescence imaging. The details about this setup are discussed in the experimental section. 
Once the “diagnostics card” and the smartphone are in place, the heater and the blue LED for 
sample illumination are turned on and real-time fluorescence imaging of the on-chip RT-LAMP 
reaction is performed using the smartphone. The reaction mix contains a double-stranded DNA 
intercalating dye which yields fluorescence as the reaction progresses. Only the channel with 
primers specific to the pathogen in patient blood sample lights up over time whereas the 
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fluorescence for the other channels remains at an initial baseline level. Amplification curves are 
generated with this real-time fluorescence data and threshold times for amplification are obtained. 
Pathogen concentration can be inferred from these threshold times using a standard curve. This 
quantitative capability of our platform becomes crucial in scenarios where changes in pathogen 
concentration in patient samples need to be monitored over time, such as for viral load monitoring 
in response to retroviral therapy in HIV patients 35, and in Dengue virus infections where high 
viremia presentation has been linked to secondary infection and disease severity 8. 
 
5.4 Characterization of RT-LAMP in a benchtop thermocycler 
 
As a first step towards our goal, we designed a novel RT-LAMP reaction for Zika virus RNA. Six 
sequence specific primers for the NS1 gene of PRVABC59 Zika virus strain (Genbank: 
KU501215) were designed (Table 5.1). Zika virus PRVABC59 was isolated from the blood of a 
human in Puerto Rico in December 2015.36 NS1 gene in Zika virus has previously been used for 
specifically detecting Zika virus using RT-PCR assay.37 Figure 5.2 shows the off-chip 
characterization of our RT-LAMP assay in a standard benchtop thermocycler apparatus. Zika virus 
RNA was purified by the Qiagen Viral Purification Kit. Figure 5.2a-b show the baseline-
subtracted change in fluorescent intensity over time for different concentrations of Zika virus 
RNA, and the corresponding threshold time against the PFU (plaque forming units) equivalent of 
purified RNA per reaction. We observed a good linear fit for the standard curve (R2= 0.9755) and 
a lower limit of detection of 10 PFU equivalent of purified RNA per reaction (reaction volume = 
25µL) corresponding to 1250 PFU/mL purified RNA in starting concentration. To compare our 
Zika virus RT-LAMP reaction with the previously published CDC RT-PCR assay for Zika virus,38 
we carried out RT-PCR experiments with same Zika virus RNA concentrations as used for RT-
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LAMP using the CDC RT-PCR primers and obtained the amplification and standard curves. 
Figure 5.2c-d show the baseline-subtracted change in fluorescent intensity over time for different 
concentrations and the corresponding standard curve for the RT-PCR assay, respectively. The 
lower limit of detection for the RT-PCR assay was found to be 1 PFU equivalent of purified RNA 
per reaction (20 µL) corresponding to 370 PFU/mL purified RNA in starting concentration. A 
similar novel RT-LAMP reaction was designed and characterized for the MR 766 
(Rhesus/1947/Uganda) strain of the Zika virus (Genbank: AY632535.2) and compared to CDC 
RT-PCR assay as shown in Figures 5.7 and 5.8. A good linear fit was observed for the standard 
curve (R2= 0.9755), and the lower limit of detection was determined to be 10 PFU equivalent of 
purified RNA per reaction which corresponded 1250 PFU/mL purified RNA starting 
concentration.  
 
As a next step, to characterize the feasibility of our developed RT-LAMP reaction from minimally 
processed samples, different concentrations of whole Zika virus were spiked in lysed whole blood 
and the reactions were performed in a thermocycler. Figure 5.2e-f show the baseline-subtracted 
change in fluorescent intensity over time for different concentrations of viruses and the 
corresponding threshold time against whole Zika virus PFU per reaction. Similar to the RT-LAMP 
reaction with purified RNA, Zika virus spiked in lysed whole blood showed a good linear fit for 
the standard curve (R2= 0.9047) and a lower limit of detection of 10 PFU per reaction in 25 µL 
tube based reactions. This corresponded to a starting Zika virus sample concentration of 6250 
PFU/mL in blood. We observed reduced fluorescence intensity in RT-LAMP reactions with lysed 
whole blood which is consistent with previous reports.9 These results show that our RT-LAMP 
reaction is robust to the debris present in lysed whole blood and serve as a proof-of-concept for 
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our on-chip reactions from processed whole blood. 
 
As our final goal was to perform multiplexed pathogen detection on the same chip, we selected 
two other closely related viruses – Dengue virus (types 1 and 3) and Chikungunya virus to 
multiplex with Zika virus on our chip. Since Zika virus infection shares symptoms with other 
febrile diseases such as Dengue and Chikungunya, accurate diagnosis is required to differentiate 
these infections during the acute phase of the disease. As RT-LAMP reactions for these pathogens 
already existed in literature39–41, we used these previously published primers (Table 5.1) and 
validated them in a tube-based thermocycler reaction.  Figure 5.10 shows the amplification curves 
for Dengue-1, Dengue-3, and Chikungunya RNA in water as a test of previously published 
primers. Figure 5.3 shows the amplification curves for the RT-LAMP reactions from Dengue-1, 
Dengue-3, Chikungunya virus, and Zika virus RNA spiked in lysed whole blood against different 
primer sets. As summarized in Table 5.2, only the specific template-primer pairs amplify in each 
of the panels validating the usability of these primer sets in multiplexing experiments. We also 
demonstrate the specificity of our Zika virus assay in the rare case of co-infection where multiple 
pathogens might be present simultaneously in the patient blood sample. As shown in Figure 5.9, 
we demonstrate in a tube-based thermocycler reaction that our assay can specifically detect Zika 
virus in the presence of Dengue-1, Dengue-3, and Chikungunya virus simultaneously in a single 
reaction.    
 
 
5.5 Microfluidic chip-based sample processing 
 
The next step towards a complete point-of-care system was to process the infected blood sample 
on-chip to make it suitable for amplification. In a two-step process, the infected whole blood was 
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first mixed with lysing buffer and then with amplification reagents in a PDMS microfluidic chip. 
Figure 5.4c shows the complete process flow and the chip layout, and Figure 5.13a shows images 
of the integrated chip. Independent characterization of this microfluidic sample processing module 
was done to compare its performance with routine manual pipetting/mixing based methods and to 
assess its potential for automation and integration with our point-of-care setup. 10 µL of whole 
blood sample spiked with 625 PFU/ μL Zika virus was metered and injected into the PDMS 
microfluidic chip concurrently with lysis buffer and RT-LAMP reagents through the labelled 
inlets. The output was collected from this microfluidic chip on four separate instances and RT-
LAMP experiments on each instance were performed on a thermocycler. As a control, four 
replicates of the same Zika virus spiked whole blood sample were mixed with lysis buffer and RT-
LAMP reagents manually using a pipette and analyzed in a thermocycler. Figure 5.4a shows the 
amplification curve for the two mixing scenarios, and Figure 5.4b shows the corresponding 
threshold time bar graphs. The threshold times for on-chip and manual sample processing 
technique were found to very similar with the deviation in the on-chip processing threshold time 
being 3.6% from the off-chip processing threshold time. The on-chip mixing was also confirmed 
visually by observing different regions of the chip during the processing step and Figure 5.4c 
shows the bright-field microscopy images of these regions. 
 
5.6 Characterization of micro-chip Zika virus RT-LAMP assay 
 
After the characterization of the RT-LAMP reactions in a thermocycler, we translated and 
characterized these reactions on our microchip and performed them on our novel point-of-care 
setup. RT-LAMP reactions with purified Zika virus RNA in water and Zika virus spiked in whole 
blood were performed on our microchip with ten-fold serial dilutions and the working range and 
limit of detection of our assays were determined. The integrated heater in our setup maintained 
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temperature 66-68 C, which was appropriate for our reactions. Figure 5.14 shows the results for 
our point-of-care setup heater characterization. Real-time images were captured by smartphone 
and threshold time analysis was performed using a MATLAB script, details about which are 
mentioned in the experimental and supplementary sections. For both sets of experiments, three 
alternating channels (in the primary hexagon shape) on the microchip, and two separate non-
template negative control channels on the chip periphery were printed with Zika virus primers. 
The remaining three channels are left unprinted to serve as on-chip no-primer controls which are 
simultaneously performed in each experimental run. Thus, our chip in total has three positive 
reaction channels, three negative no-primer control channels and two negative no-template control 
channels as shown in the chip layout (Figure 5.5). Together they ensure that the amplification 
results obtained are from specific Zika virus reactions only and not from spurious, non-specific 
amplification.    
 
For the on-chip RT-LAMP characterization with purified RNA, template (purified RNA in water) 
and the RT-LAMP reagents without primers were mixed manually using a pipette, and 7 µL of the 
final reaction mix was injected into the amplification chip (module B) using a syringe pump. The 
chip was sealed to prevent evaporation (See methods for details) and contamination, and the 
diagnostics card consisting the amplification chip was inserted into the cradle. Figure 5.5a shows 
the time-lapsed fluorescence images of a representative RT-LAMP reaction on-chip showing the 
amplification of only positive channels. The images shown are for RT-LAMP reaction from 10 
PFU equivalent of purified RNA per microliter of Zika virus. Figure 5.5b-d show the raw 
amplification curves, the amplification curves after sigmoidal fitting, and the threshold-time 
standard curves for these reactions. The details about sigmoidal fitting analysis are mentioned in 
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the experimental section and illustrated in Figure 5.12. We observe a lower limit of detection of 
purified RNA equivalent to 10 PFU per µL of final reaction (1 channel = 1 reaction = 1µL volume) 
corresponding to 3.125e4PFU/ mL in starting concentration). A good linear fit was observed in 
the standard curve (R2 = 0.99) with distinct threshold times per ten-fold change in template 
concentration.  
      
The complete diagnostics card with the sample processing chip (module A) connected to the 
amplification chip (module B) as shown in Figure 5.1b, was used to characterize the RT-LAMP 
reactions with Zika virus in whole blood. The Zika virus infected blood sample was first processed 
in module A as described in the previous section and then allowed to flow directly into the 
amplification chip. Upon filling, the chip was sealed, and the diagnostics card was inserted into 
the cradle (point-of-care setup). The cradle design allows the amplification chip to sit snugly on 
top of the heater while the sample processing module sticks out as shown in Figure 5.13a. Figure 
5.5e-g show the raw amplification curves, the amplification curves after sigmoidal fitting, and the 
threshold-time standard curves for these reactions A good linear fit was observed in the standard 
curve (R2 = 0.9913) with Zika virus detection down to 10 copies per µL of final reaction (1 channel 
= 1 reaction = 1µL volume) corresponding to 1.56e5 PFU/ mL starting virus concentration. With 
clinically significant detection limits from infected blood samples, the results of this experiment 
demonstrated that our on-chip assay can successfully monitor viral loads via RT-LAMP reactions 
that employs hands-free sample processing, a portable cradle setup, and smartphone-based 
imaging that can be easily translated for use at the point-of-care. 
 
5.7 Multiplexed pathogen detection on microchip 
 
Our platform was put to the final test of analyzing samples containing different pathogens on the 
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diagnostics card. Zika virus, Dengue-1, Dengue-3, and Chikungunya virus primers were 
simultaneously printed in different channels on our amplification chip (module B) per the pattern 
shown in Figure 5.6. The complete integrated setup was used for these experiments to demonstrate 
their efficacy in a clinical setting. The chips were challenged with either 1.56e4 PFU/µL of whole 
Zika virus in starting blood sample or 1.56e4 copies/µL of purified RNA of either Dengue-1, 
Dengue-3, or Chikungunya virus in starting blood sample and separate point-of-care RT-LAMP 
experiments were performed. Figure 5.6a-d show the multiplexed detection of Zika virus, 
Dengue-1, Dengue-3, and Chikungunya virus from whole blood respectively. In each of the case, 
we observe that only the lanes with specific template-primer set amplify while the remaining lanes 
remain at baseline fluorescence during the entire reaction. These reactions demonstrate the 
capability of our platform to specifically diagnose and provide clinically actionable information 
for different pathogens at the point-of-care from infected whole blood samples.  
 
5.8 Chapter summary 
 
Among the barriers to more effective management of Zika virus outbreaks, such as the recent 
episode in South and Central America, is the lack of an adequate tools for diagnosis. Neither 
clinical presentation nor serology testing can reliably distinguish Zika from other mosquito-borne 
viruses like Dengue and Chikungunya, yet early identification of Zika infection is critical to 
minimizing human-to-human transmission and preventing potentially devastating sequelae, such 
as fetal microcephaly.2 Recent reports have included higher viral loads and much longer 
persistence of viruses detectable in whole blood compared to plasma, urine, and other biological 
samples. However, none of the point-of-care approaches on Zika infection detection to date have 
tapped into the erythrocyte-associated viral load component. Enabling regular detection of these 
viruses in whole blood may allow for new, clinically-relevant information not available in assays 
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which only assess plasma or serum viral load. For example, this could elucidate relationships 
between detectable erythrocyte-associated virus fraction and transmission potential of an infected 
individual. We have demonstrated detection of Zika virus as low as 1.56e5 PFU/mL from whole 
blood with a microchip and smartphone-based point-of-care platform. While reports are varied, 
the viral loads in only the serum component of whole blood have been documented as high as 1e6 
PFU/mL42, and hence, we believe our technique is capable of addressing the clinically-relevant 
range when testing from whole blood samples. This makes our work one of the most compelling 
approaches yet to be reported toward making available a practical tool for Zika diagnostics due to 
its rapid performance, portable format, and ability to distinguish Zika from related infections. 
Furthermore, we expect limit-of-detection can be further improved in subsequent iterations of this 
technology to meet the need to detect even very low viremia at the point-of-care. 
Furthermore, our approach is capable of quantitative analysis of viral load which is likely to prove 
valuable in the understanding of a previously little-known pathogen. For example, one report has 
associated high viremia with hospitalization and increased severity of symptoms,8 so a quantitative 
measure of viral load may prove valuable in triage or guidance of anticipatory management of 
individuals with confirmed infection. Meanwhile, another report identified very high viremia in a 
case in which non-sexual, close-contact transmission took place,4, suggesting that the ability to 
quantitate viral loads may inform the need for contact precautions or quarantine8. Low reagent 
consumption and the ability to test for multiple pathogens on a single pre-printed microchip is the 
basis for our platform’s potential to achieve low-cost testing from a simple finger prick. The 
process is compatible with freeze-drying methods which would enable single-use, disposable 
biochips to be prepared and stored before rehydrating in a re-usable system. Our battery-powered 
3-D printed cradle with an embedded optical detection system and integrated heater, coupled with 
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smartphone imaging also lends itself to portable and user-friendly operation with low instrument 
costs. The smartphone gives real-time visual output of the test which can be interfaced directly 
with an external computer or completely self-contained with data analysis performed by a mobile 
application. The clear integration with mobile communications technology allows personalized 
patient care and facilitates information management for both healthcare providers and 
epidemiological surveillance efforts. Finally, while we have demonstrated the multiplexing of 
Zika, Dengue type 1, Dengue type 3 and Chikungunya viruses from whole blood, our platform 
exhibits the flexibility to incorporate alternative or additional targets simply by preparing the 















































Figure 5.1| Schematic and POC process flow of the ZCD Viral Detection system. 1. Patient sample 
form a finger prick of blood is collected and loaded into the pre-processing module. 2. Automated on-
chip mixing of the sample with the lysis buffer and RT-LAMP reagents takes place within minutes in 
sample processing module (module A). 3. The complete reaction mix is loaded onto the amplification 
chip (module B). 4. The amplification module is completely sealed and ZCD Viral Diagnostics Card is 
inserted into the cradle. 5. The smartphone is positioned on top of the cradle and focused to image the 
entire chip. The heating switch is turned on to incubate the amplification chip for the RT-LAMP 
reaction. The silicon amplification chip sits atop the heating element and is in contact with the heater 
during the entire RT-LAMP incubation process. 6. The LED switch is turned on for sample illumination.  
7. Real-time fluorescence imaging of the amplification reaction is performed using the smartphone and 
the results of the RT-LAMP reaction are visually displayed on the smartphone screen. The lighting up 








Figure 5.2| Thermocycler based Zika virus RT-LAMP reaction characterization. (a-b) Baseline-
subtracted raw amplification curves showing the change in fluorescence over time and the calculated 
standard curve of the RT-LAMP assay for Zika virus PRVABC59 purified RNA. (c-d) Baseline-
subtracted raw amplification curves showing the change in fluorescence over time and the standard 
curve of the RT-PCR assay for Zika virus PRVABC59 purified RNA. This assay was performed using 
previously published primers 38.   (e-f) Baseline-subtracted raw amplification curves showing the change 
in fluorescence over time and the standard curve of the RT-LAMP assay for whole Zika virus 
PRVABC59 spiked in lysed whole blood. The results demonstrate the range and lower limit of detection 
of our assay in thermocycler based reactions from purified Zika virus RNA and whole Zika virus in 




Figure 5.3| Off-chip multiplexing of four viral targets. Baseline-subtracted raw amplification curves 
showing the changes in fluorescence over time in separate RT-LAMP reactions to detect (a) Zika virus 
(b) Dengue-1 virus (c) Dengue-3 virus, and (d) Chikungunya-virus templates. All the templates were 
challenged with all the primer sets and the result demonstrates that only the correct template-primer pair 
amplifies. The template in Fig.s a-c contain 1000copies/reaction (25 µL volume) of Dengue-1, Dengue-
3 and Chikungunya purified RNA spiked in lysed whole blood. The template in Fig. d contains 










Figure 5.4| Microfluidic sample processing characterization. (a) Baseline-subtracted raw 
amplification curves showing the changes in fluorescence over time for on-chip and off-chip sample 
processing (blood lysis and reagent mixing) using whole blood sample containing 625 PFU/µL Zika 
virus. (b) Threshold-time bar graphs comparing the on-chip and off-chip sample processing. The final 
product of the microfluidic mixing was pipetted into tubes and thermocycler based RT-LAMP reactions 
were performed. Control thermocycler based RT-LAMP reactions with same Zika virus in blood 
concentrations were performed after sample processing through manual pipetting. (c) Images showing 
mixing of the blood-lysis buffer- amplification reagents at different points in the channels of the sample 











Figure 5.5| On-chip RT-LAMP assay characterization. (a) Raw fluorescence images of the 
amplification chip at time = 0, 14, 28, and 42 mins respectively showing the amplification of only 
positive channels for RT-LAMP reaction with purified RNA. The images shown are for 1e1 PFU 
equivalent of purified RNA/µL of Zika virus in final reaction.  (b) Raw amplification curves of the Zika 
virus RT-LAMP assay on-chip carried out from purified RNA, and (c) the same amplification curves 
after sigmoidal fitting. (d) The standard curve of the Zika virus RT-LAMP assay with purified RNA. A 
lower limit of detection of 3.125e4 PFU equivalent of purified RNA /mL in starting sample of Zika virus 
RNA in water was observed. (e) Raw amplification curve of the Zika virus RT-LAMP assay on-chip 
carried out with whole viruses in whole blood and (f) the same amplification curves after sigmoidal 
fitting. (g) The standard curve of the Zika virus RT-LAMP assay with virus in whole blood. A lower 
limit of detection of 1.56e5 PFU per mL of Zika virus in starting infected blood sample was observed. 
























Figure 5.6| On-chip multiplexing of four viral targets. Raw fluorescence images of the amplification 
chip at t=0, 14, and 28 minutes respectively and raw amplification curves of the RT-LAMP reaction 
showing multiplexed detection of (a) Zika virus (b) Dengue-1 viral RNA (c) Dengue-3 viral RNA, and 
(d) Chikungunya viral RNA from infected whole blood samples in four separate experiments using the 
same chip layout with pre-printed primers. Primers for each of these pathogens were simultaneously 
printed in different channels of the chip and this layout was kept constant across the different on-chip 
multiplexing experiments. The starting concentration of Zika virus and the other viral RNAs in blood 




Figure 5.7| Off-chip RT-LAMP characterization of Zika virus MR-766 strain. (a-b) Baseline-
subtracted raw amplification curves showing the changes in fluorescence over time and the calculated 
threshold-time curve of the RT-LAMP assay designed to detect Zika virus MR-766 purified RNA. This 
primer set was specific to the MR-766 strain only and not the PRVABC59 strain. The same was the case 





Figure 5.8| Off-chip RT-PCR characterization of Zika virus MR-766 strain. (a-b) Baseline-
subtracted raw amplification curves showing the changes in fluorescence over time and the standard 

















Figure 5.9| Co-infection test. Baseline-subtracted RT-LAMP raw amplification curves showing the 
changes in fluorescence over time to detect purified Zika virus RNA in the presence of closely related 
contaminating RNA. 3 different scenarios of Zika virus infection: 1. Zika virus with contaminating 
RNA, 2 Zika virus without contaminating RNA, and 3. Contaminant without the Zika virus RNA were 
tested. The first two cases yielded amplification and similar threshold times, whereas the final scenario 
did not yield any amplification confirming the specificity of our designed primer to Zika virus even in 
the presence of multiple contaminating RNA. The contaminants included a mixture of Dengue-1, 
Dengue-3, and Chikungunya virus purified RNA, all at the concentration of 1000 copies per reaction. 























Figure 5.10| Off-chip RT-LAMP assay validation. Baseline-subtracted raw amplification curves 
showing the changes in fluorescence over time for different template-primer set pairs to validate and 
determine the working primer sets for future experiments. A second validation experiment was carried 
out by spiking the RNA of the above flaviruses in lysed and carrying out RT-LAMP reaction. The data 




















Figure 5.11| On-chip assay with virus in blood. (a) Raw fluorescent image of the chip at t=0,14,28, 
and 42 mins respectively. (b) Raw amplification curves showing the changes in fluorescence over time. 
(c) Amplification curves after sigmoidal fitting showing that only the positive lanes amplify while the 














Figure 5.12| Sigmoidal fitting of raw amplification curves. Sigmoidal fitting on 
representative data from a positive and negative channel using the 4 point parameter 
model described in experimental section. The threshold time was taken as the time when 












Figure 5.13| Microfluidic chip and cradle setup. (a) Image of the integrated chips (before experiment) 
in a credit card sized holder (left). Image of a filled and completely sealed chip after the pre-processing 
steps (top right), and image of the smartphone cradle setup imaging the chip (bottom right). The credit 
card-sized holder can be inserted into the cradle such that the amplification chip sits snugly atop the 
heater and the pre-processing chip sticks out. The holder can be readily removed after the experiment. 

















Figure 5.14| Cradle Heater Characterization. Temporal temperature gradients measured from five 
different points on the microfluidic chip. The temperature reaches at 65 ˚C in 5 minutes after the heater 
beneath the chip is turned on and is kept above 65 ˚C over 65 minutes. Inset shows the temperature 
gradients of the points marked on the chip for 60 minutes to perform one LAMP assay. Each point 
represents an average value from three independent measurements, and the error bars represent three 





The RT-LAMP and RT-PCR primer sequences used in this study were synthesized by Integrated DNA Technologies 




F3: GAC CCC ATC AAC GTG GTG 
B3: CCA CAC TCT TTC CTG AGA CC 
FIP: TCA GGC CAA CAG CTG TGA GTA CGA CTG CTG TTG CTC ACA AGG 
BIP: CGC ATT GGC TGG AGG GTT CGT GAC AAT TAG CAG ACC GAC C 
Loop F: CAG CTC CGC TTC CCA CT 
Loop B: AGG CAG ATA TAG AGA TGG CTG G 
MR-766 RT-
LAMP primers 
F3: TTC GTG GAG GGC ATG TCA 
B3: GAC TGT CCG AAG CCA TGT C 
FIP: CCT GTG CCA TCA CGG TAA CGC GGT GGG ACC TGG GTT GAT 
BIP: TAG AGT TGG TCA CGA CGA CGG TCG ATA TCG ATG CCT CGT AGC 
Loop F: AGC CTC CAT GTT CCA AGA CAA 
Loop B: AAC ATG GCC GAG GTA AGA TCC 
Dengue-1 RT-
LAMP primers 
F3: TGT GTT CCT CCT TCT CAT AAT G 
B3: CAG ACT CAA TCC AAT CGT AAG A 
FIP: CAT CCT GTC TGA AGC ATT GGC TGG ACA ATT GAC ATG GAA TGA TC 
BIP: CCT AGC TCT GAT GGC CAC TTT CTT CTC TAG ATG TTA GTC TGC G 
Loop F: CCA ACC ATG ATG CAT AAC CTG 
Loop B: ATG AGA CCA ATG TTC GCT GT 
Dengue-3 RT-
LAMP primers 
F3: CCC GTC CAA GGA CGT TAA 
B3: CTG CTG CGT TGT GTC ATG 
FIP: CG ACG GAG CTA CAG GCA GAA GAA GTC AGG CCC AAA 
BIP: GGG ACG TAA AGC CTG GGA GCC TCT AAC CAC TAG TCT GCT A 
Loop F: GTT TGC TCA AAC CGT GGC 




F3: ACG CAA TTG AGC GAA GCA C 
B3: CTG AAG ACA TTG GCC CCA C 
FIP: CGG ATG CGG TAT GAG CCC TGT ATG GAG AAG TCC GAA TCA TGC 
BIP: TCC GCG TCC TTT ACC AAG GAA ATT TGG CGT CCT TAA CTG TGA C 
Loop F: GCT GAT GCA AAT TCT GT 
Loop B: CCT ATG CAA ACG GCG AC 
Zika Envelope 
RT-PCR primers  
Forward: CCG CTG CCC AAC ACA AG 
Reverse: CCA CTA ACG TTC TTT TGC AGA CAT 
































Table 5.2| Summary of all template-primer tests. To validate our on-chip multiplexing, we carried 
out off-chip RT-LAMP reactions to validate each template-primer assay combination. This table 
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Chapter 6: Conclusions and Future outlook  
 
Micro-nano scale platforms offer exciting opportunities to realize the goal of personalized 
medicine in cancer and infectious diseases. For spatial molecular analysis of cancer tissue, we 
showed a microchip platform that can perform on-chip picoliter real-time reverse transcriptase 
loop mediated isothermal amplification (RT-LAMP) reactions on a histological tissue section 
without any analyte purification while preserving the native spatial location of the nucleic acid 
molecules. This platform could produce a spatial map of target mRNA (TOP2A) starting from 
tissue cryosection in less than 2 hours. In comparison to laser capture microdissection (LCM) 
based techniques, this was a major step forward as our technique allowed automated tissue 
microdissection directly on the microchip followed by spatially mapped target mRNA 
amplification in the microwells. Our technique, which can be easily performed in routine practice, 
has many important clinical and biological applications such as understanding tumor 
heterogeneity, predicting patient outcomes, and post-operative characterization of surgical 
margins. However, due to limitations of amplification-based techniques in general, we can only 
look for a limited number of targets on chip simultaneously due to problems with non-specific 
amplification when a greater number of primer sets are present. To look at the expression of many 
targets simultaneously from the same tissue section, spatial transcriptomics would be the way 
forward. However, that also comes with higher sequencing costs and higher processing times, 
which at this time which might not be clinically possible. 
Another aspect of the personalized medicine in cancer, is the empirical drug testing directly on 
organoids grown from patient biopsy and creating a database of mapped genomic alterations to 
data on drug sensitivity to guide future patient care. Three dimensional cultures have been shown 
to produce in-vivo like culture conditions which can help them recapitulate morphological and 
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cellular characteristics relevant to in-vivo tumor. Towards this, we showed a microscale 
platformed coined the ‘Nano hanging drop culture’ where individual nano-litre sized (10.8nL) 
hanging droplets are held by capillary forces inside inverted silicon oxide-on-silicon micro-wells 
in oil. Organoid formation on our platform happens in less than 1 day due to increased cell-cell 
interactions within the nano-droplet and without the need for any specific medium or matrices that 
can put selective pressure and bias tumor evolution during culture. Although several three-
dimensional culture techniques currently exist to produce organoids, they do not allow real time 
microscopy-based characterizations and individual organoid tracking, or high-resolution confocal 
analysis directly on the platform. We demonstrated our platform by culturing nano hanging drop 
organoids from human glioblastoma cell line and patient derived xenograft cells and showed that 
these organoids show similar protein expression profiles to those observed in vivo in human tumor 
xenografts. We also demonstrate the feasibility of drug testing directly on chip with real time 
microscopy-based monitoring of organoids for response to drug with days. As a next step to our 
platform development, we will process direct patient biopsy samples on our chip and form tumor 
organoids. Our final goal with this platform is translation into the routine clinic pipeline, where 
patient samples directly cultured on our platform can be used for direct drug testing and help guide 
patient treatment in the clinic. 
On the biosensing side of our work in personalized medicine, we showed label free sensing of 
microRNA using a chip with more than 1 million ion sensitive field effect transistors (ISFET). 
Label free techniques offer exciting opportunities for portable personalized diagnostics and health 
surveillance platforms due to their small footprint. However, our current platform of ISFET 
devices had lower sensitivity with limit of detection of 1nM microRNA conc. In the future, for 
these devices to be commercialized in the diagnostics arena the sensitivity will have to be improved 
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to be able to detect pico-to-femtomolar analyte concentrations. In the same biosensing theme, we 
also showed a portable point-of-care diagnostic setup using a smartphone-based setup for 
fluorescence imaging. We used this setup to detect zika virus specifically and distinguish it from 
other viruses in the flavivirus family using real time loop mediated isothermal amplification 
reaction. This platform can allow personalized medicine to reach remote areas of the world that 
lack clinical labs and other diagnostic infrastructure where currently treatment is only based on 
symptoms.   
 
 
